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ABSTRACT  
Genome-wide association studies (GWAS) have revealed increased breast cancer risk associated 
with multiple genetic variants at 5p12. Here, we report the fine-mapping of this locus using data 
from 104,660 subjects from 50 case-control studies in the Breast Cancer Association Consortium 
(BCAC). Using data for 3,365 genotyped and imputed single nucleotide polymorphisms (SNPs) 
across a 1Mb (positions 44394495-45364167; NCBI build 37) panel we found evidence for at 
least three independent signals: the strongest signal, consisting of a single SNP rs10941679, was 
associated with risk of estrogen receptor-positive (ER
+
) breast cancer (per-g allele OR ER
+
=1.15; 
95% CI 1.13-1.18; P=8.35x10
-30
). After adjustment for rs10941679, we detected signal 2, 
consisting of 38 SNPs more strongly associated with ER-negative (ER
-
) breast cancer (lead SNP 
rs6864776: per-a allele OR ER
-
=1.10; 95% CI 1.05-1.14; P-conditional=1.44E
-12
); and a single 
signal 3 SNP (rs200229088: per-t allele OR ER
+
=1.12; 95% CI 1.09-1.15; P-conditional=1.12E
-
05
). Expression quantitative trait locus analysis in normal breast tissues and breast tumors showed 
the g (risk) allele of rs10941679 was associated with increased expression of FGF10 and 
MRPS30. Functional assays demonstrated that SNP rs10941679 maps to an enhancer element 
that physically interacts with the FGF10 and MRPS30 promoter regions in breast cancer cell 
lines. FGF10 is an oncogene that binds to FGFR2 and is over-expressed in ~10% of human 
breast cancers, while MRPS30 plays a key role in apoptosis. These data suggest that the strongest 
signal of association at 5p12 is mediated through coordinated activation of FGF10 and MRPS30, 
two candidate genes for breast cancer pathogenesis.  
 
Strong evidence for the existence of a breast cancer [MIM 114480] susceptibility locus at 5p12 
has been observed through a GWAS in Iceland (SNP rs7703618),
1
 in the Breast Cancer 
Association Consortium (BCAC; SNP rs981782, 371Kb centromeric)
2
 and in the Cancer 
GEnetic Markers of Susceptibility study (CGEMS; SNP rs4866929; 352Kb centromeric; 
r
2
=0.18).
3
 A subsequent study, using 22 SNPs in ~5000 cases and ~33,000 controls of European 
ancestry, reported that risk at this locus could be explained by two SNPs: rs4415084 and 
rs10941679.
4
 More recently, a BCAC study confirmed that rs10941679 was associated with risk 
of lower-grade, progesterone receptor (PGR [MIM 607311])-positive breast cancer tumors.
5
  
Here, we report the comprehensive fine-scale mapping of this locus in 104,660 subjects from 50 
case-control studies participating in BCAC, including 41 studies from populations of European 
ancestry and nine of East Asian ancestry, and explore the functional mechanisms underlying the 
associations in this region. Genotyping was conducted using the COGS array, a custom array 
comprising approximately 200,000 SNPs.
6
 After quality control exclusions, we analysed data 
from 48,155 cases and 43,612 controls of European ancestry and 6,269 cases and 6,624 controls 
of Asian ancestry. Estrogen receptor (ESR1 [MIM 133430]) status of the primary tumor was 
available for 27,748 European and 4,997 Asian cases; of these 7,646 (22%) European and 1,623 
(32%) Asian cases were ER
-
.  
 
We examined a 1Mb region (positions 44394495-45364167; NCBI build 37 assembly) in which 
the 1000 Genomes Project catalogued 1,811 variants (March 2010 Pilot version 60 CEU project 
data). We aimed to genotype all 628 SNPs with minor allele frequency (MAF)>2% and 
correlated with rs981782 and rs10941679 at r
2
>0.1 (N=424), plus a set of SNPs designed to tag 
all remaining SNPs with r
2
>0.9 (N=184); but managed to include 563 SNPs with a designability 
score (DS)>0.9 and which passed QC
6
. IMPUTE version 2.0 was used to impute genotypes of all 
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known SNPs in the region using the 1000 Genome Project data (March 2012 version) as a 
reference panel.  
 
Case-control analyses were conducted on 3,365 SNPs (563 genotyped and 2,776 imputed at 
r
2
>0.3). In European-ancestry women, 461 of these SNPs were associated with overall breast 
cancer risk, 489 with ER
+
 and 38 with ER
-
 breast cancer risk (P<10
-4
; Table S1). SNP 
rs10941679 showed the strongest overall association (MAF=0.27, per-minor (g) allele: OR=1.12; 
95% CI 1.10-1.14; P=2.55x10
-26
; Figure 1, Table 1 and Table S1). To identify additional 
association signals at this region, we conducted a forward stepwise logistic regression examining 
SNPs with univariate P <0.1 (N=1,040).
6
 The most parsimonious model included three variants: 
SNP1 rs10941679 (signal 1), SNP2 rs6864776 (signal 2; conditional P=6.22x10
-11
) and SNP3 
rs200229088 (signal 3; conditional P=1.12x10
-5
, borderline significance; Table S2). SNP1 and 
SNP3 are weakly correlated (r
2
=0.15) but SNP2 was uncorrelated with the other two (r
2
=0.07 
and 0.05).  
 
The top signal, SNP1 (rs10941679), is markedly more significant than any other SNP in the 
locus (likelihood ratio >10,000:1). Hence, the most parsimonious explanation is that this SNP is 
causally related to risk. The next most strongly associated SNP, after adjustment for signal 1 
SNP rs10941679, was rs6864776, representing signal 2 (OR per minor allele=1.04; 95% CI 1.02-
1.06; P=7.84x10
-4
; conditional P=1.44x10
-12
). Within signal 2, a further 37 SNPs correlated with 
rs6864776 at r2>0.6, had likelihood ratios of <100:1 relative to rs6864776 and hence could not 
be excluded from being causative statistically (Table S2). After adjustment for both signal 1 
SNP rs10941679 and signal 2 top SNP rs6864776, a single SNP remained: rs200229088 (OR 
overall=1.09, 95%; CI 1.07-1.12; P=2.28x10
-12
; conditional P=1.12x10
-5
). There are no other 
SNPs correlated with rs200229088, which could explain this association. All other SNPs were 
excluded from causality (likelihood ratio >10,000:1; Table S2). Two of the excluded variants 
had been previously postulated as likely causative variants
4,7
 and so we investigated these in 
more depth. We found both SNPs to be partially correlated with all three signals and 
consequently display initially inflated effects, which are adjusted by the conditional analyses. 
Thus, SNP rs4415084
4
 (r
2
 with signal 1 SNP rs10941679=0.51; with signal 2 SNP 
rs6864776=0.11 and with signal 3 SNP rs200229088=0.37) has odds against causality >10 
million:1 versus Signal 1 candidate rs10941679. Similarly, SNP rs7716600, which is an eQTL 
for MRPS30 expression
7 
(r
2 
with SNP rs10941679=0.77; with SNP rs6864776=0.05 and with 
SNP rs200229088=0.12 has odds against causality>160,000:1 versus signal 1 candidate 
rs10941679). These exclusions of former causal candidates highlight the need for fine-mapping 
studies before conducting functional analyses. 
 
Haplotype analyses were conducted using the above three signal-representative variants, which 
generated eight haplotypes (Table 2). Haplotypes carrying the rare allele of signal 3 SNP 
rs200229088 conferred higher risks than corresponding haplotypes carrying the common allele, 
consistent with this allele having an independent effect. Haplotype G, carrying the minor alleles 
of both the signal 1 and 2 representative SNPs, is very rare and reveals that their risk alleles are 
negatively correlated, this is also consistent with our finding that signal 2 top SNP rs6864776 
increases in significance after conditioning on signal 1 SNP rs10941679 (Table 1).  
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We examined the associations of these three SNPs in the Asian case-control studies within 
BCAC. SNP1 and SNP3 both replicated in the Asian studies and the relative risk estimates with 
overall breast cancer were consistent with those seen in the European population: per g-allele OR 
(rs10941679)=1.09; 95% CI 1.04-1.15; P=0.0009, conditional P =0.0859 and per t-allele OR 
(rs200229088)=1.09; 95% CI 1.02-1.15; P=0.0065, conditional P = 0.9149 (Table 1). SNP2 was 
not replicated in Asians (per a-allele OR=0.94; 95% CI 0.89-1.00; P=0.034, conditional 
P=0.8901 (Table 1). 
 
We investigated the associations of these three signals with tumor-subtypes based on ER status. 
SNP1, rs10941679, was largely associated with ER
+
 breast cancer (OR ER
+
=1.15; 95% CI 1.13-
1.18; P=8.35x10
-30
 versus OR ER
-
 disease=1.04; 95% CI 1.00-1.08; P=0.059; P-
heterogeneity=1.5x10
-5
; Table 1) as was SNP3, rs200229088 (OR ER
+
=1.12; 95% CI 1.09-1.15; 
P=7.51x10
-14 
versus
 
OR ER
-
=1.03; 95% CI 0.99-1.09; P=0.11, P-heterogeneity=0.02). By 
contrast the SNP2, rs6864776, was moderately associated with ER
-
 but not with ER
+
 tumors (OR 
ER-=1.10; 95% CI 1.05-1.14; P=2.55x10
-5
 versus OR ER
+
=1.02; 95% CI 0.99-1.05; P=0.08; P-
heterogeneity=0.01; Table 1).  
 
Candidate SNPs 1-3 span a 1.7 Mb region on 5p12 that includes three annotated genes; FGF10 
[MIM 602115], MRPS30 [MIM 611991] and HCN1 [MIM 602780] and several putative long 
noncoding RNAs (lncRNAs; Figure 1). To identify potential target gene(s), we examined the 
associations of the three lead SNPs with expression levels of genes located within 1 Mb in three 
different studies: (1) 116 normal breast samples and 241 breast tumors from the Norwegian 
Breast Cancer Study (NBCS).
8
 (2) 93 normal and 765 breast cancer tissues from the TCGA study. 
Germline genotype data from Affymetrix SNP 6 array were obtained from TCGA dbGAP data 
portal.
9
 (3) 183 normal breast samples from the Genotype-Tissue Expression (GTEx) project.
10
 
The SNP1 rs10941679 risk-associated g-allele was moderately associated with increased FGF10 
mRNA expression in NBCS normal breast (P=0.013, P-corrected=0.39) and breast tumors 
(P=0.005, P-corrected=0.38), as well as in GTEx normal breast (P-corrected =0.02; Figure 2a 
and Figure S1a). The effect in TCGA was in the same direction, though not significant (normal 
breast P=0.353, P-corrected=0.95 and P=0.057, P-corrected=0.41 in breast tumors; Figure S1b). 
The g-allele was also associated with increased expression of MRPS30 in the NBCS normal 
(P=0.002, P-corrected=0.36) and breast tumors (P=0.049, P-corrected=0.43), in GTEx normal 
breast (P-corrected=0.002) and in TCGA (normal breast P=6.86x10
-5
, P-corrected=5.31x10
-3
 
and breast tumors P=7.21x10
-6
, P-corrected=9.35x10
-4
, Figure 2b and Figure S1a,c). No 
associations were observed with SNP2, rs6864776 or SNP3 variant, rs200229088. We also 
measured endogenous levels of FGF10, MRPS30 and nearby lncRNAs FGF10-AS1, BRCAT54, 
RP11-503D12.1 and RP11-473L15.3 mRNA in breast cell lines homozygous (A/A or G/G) or 
heterozygous (A/G) for the common allele of SNP1 (Table S3, Figure 2c,d and Figure S2, S3). 
Total RNA from cell lines was extracted using Trizol and complementary DNA synthesized 
using random primers as per manufacturers’ instructions. Quantitative PCR (qPCR) were 
performed using TaqMan assays for FGF10 and MRPS30 normalized against beta-glucuronidase 
(GUSB [MIM 611499]) or with SYTO9 for lncRNAs normalized against TATA box-binding 
protein (TBP [MIM 600075]; primers are listed in Table S4). While the number of ER
+
 breast 
cell lines carrying the risk allele was limited, FGF10 and MRPS30 mRNA levels were 
significantly higher in the BT474 heterozygous cell line (Figure 2c,d). BRCAT54 was detected 
in the majority of cell lines but its expression appears to be genotype-independent (Figure S3a). 
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FGF10-AS1, RP11-503D12.1 and RP11-473L15.3 transcripts were either expressed at very low 
levels or not detected in the cell lines analyzed (Figure S3b-d). Therefore, while we cannot rule 
out the possibility that the risk SNPs may influence local lncRNA expression, the low or absent 
transcript levels precluded any further evaluation. 
 
Candidate causal SNPs were then explored using publicly available datasets from ENCODE
11
, 
which includes information such as the location of promoter and enhancer histone marks, open 
chromatin, bound proteins and altered motifs for the MCF7 breast cancer cell line, and from 
Hnisz et al
12
 and Corradin et al
13
, to identify the location of likely enhancers and their gene 
targets in a cell-specific context. Analysis of cis enhancer-gene interactions using PreSTIGE
13
 
showed evidence of putative regulatory elements (PREs) surrounding the top risk-associated 
SNPs in MCF7 breast cancer cells, but no histone marked elements harboring a risk SNP in this 
cell line or in a range of cell lines and tissues analyzed in Roadmap (Figure 1 and S4). However, 
it is possible that certain epigenetic marks may only be detected in a specific cell subtype such as 
breast stem cells or in response to an external stimulus. 
 
To identify target gene(s), we performed chromatin conformation capture (3C) assays in ER
+
 
MCF7, BT474 and MDA-MB-361 and ER
-
 MDA-MB-231 breast cancer cell lines and Bre80 
normal breast cells (Table S5).
8
 3C libraries were created by cross-linking the chromatin from 
cell lines; DNA was then digested with EcoRI, which flanks 12 contiguous fragments that cover 
the PRE, and the FGF10, MRPS30 and HCN1 promoters (Table S6); DNA was religated and 
decrosslinked; and qPCR with primers for the bait (gene promoters) and interactors (12 PRE 
fragments) was performed to detect the presence of ligation products, representing gene loops. 
BAC clones covering the regions of interest were used to normalize for PCR efficiency. These 
assays showed that the PRE containing SNP1 frequently interacted with the FGF10 and MRPS30 
promoter regions in MCF7 and BT474 breast cancer cell lines, but only with MRPS30 in the 
MDA-MB-361, MDA-MB-231 and Bre80 cell lines. This latter result was expected as FGF10 is 
not expressed or expressed at very low levels in these cell lines (Figures 2c, 3a, S5 and S6). 
Notably, both genes share a bidirectional promoter with the lncRNAs FGF10-AS1 and BRCAT54, 
raising the possibility that these transcripts are also targets of the PRE (Figure 3a). No additional 
interactions were detected between the PRE and other annotated genes within 1Mb of the PRE, 
including HCN1 (Figure S5). To assess the potential impact of SNP1 on the identified chromatin 
interactions, allele-specific 3C was performed in heterozygous BT474 cell lines
8
. However, the 
sequence profiles revealed that SNP1 had no significant effect on chromatin looping (Figure S7).  
 
The regulatory capability of the PRE, combined with the effect of SNP1, was further examined 
in reporter assays. Promoter-driven luciferase reporter constructs were generated by the insertion 
of PCR amplified fragments containing FGF10, FGF10-AS1, MRPS30 or BRCAT54 promoters 
into pGL3-Basic.
14
 A 1,736bp PRE fragment (containing either the common or minor allele of 
rs10941679) was then generated by PCR and cloned downstream of the modified pGL3-
promoter constructs (Table S7). MCF7 and BT474 breast cancer cell lines plus Bre80 normal 
breast cells were transfected with the reporter plasmids and luciferase activity was measured 
24hr post-transfection. To correct for any differences in transfection efficiency or cell lysate 
preparation, Firefly luciferase activity was normalized to Renilla. Notably, the ‘Ref PRE’ acted 
as a transcriptional enhancer, leading to a 2–3 fold increase in FGF10, MRPS30 and BRCAT54 
promoter activity, but had no effect on the FGF10-AS1 promoter in MCF7 and BT474 cells 
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(Figures 3b and S8). The enhancer activity was also observed for the MRPS30 and BRCAT54 
promoters in Bre80 cells (Figure S8). In all cell lines, inclusion of the SNP1 risk (g) allele had 
no significant effect on the PRE enhancer activity. While this appears to rule out an effect of this 
SNP on transactivation, it is possible that SNP1 affects the recruitment of key proteins required 
for the epigenetic modification of the enhancer, which would not be observed in a reporter assay. 
Another possibility is that the SNP effect may only be observed under certain biological 
conditions such as growth factor stimulation.  
 
To seek further evidence that SNP1 lies within an enhancer element we performed 
electrophoretic mobility shift assays (EMSAs) for both the protective (a) and risk (g) alleles.
15
 
Nuclear lysates were prepared from ER
+
 BT474, MCF7 and MDA-MB-361 or ER
-
 MDA-MB-
231 and Hs578T cells using the NE-PER nuclear and cytoplasmic extraction reagents. 
Biotinylated oligonucleotide duplexes were prepared by combining sense and antisense 
oligonucleotides, heat annealing and slow cooling. Duplex-bound complexes were transferred 
onto Zeta-Probe positively-charged nylon membranes by semi-dry transfer then cross-linked 
onto the membranes. Membranes were processed with the LightShift Chemiluminescent EMSA 
kit as per the manufacturer’s instructions, and signals visualized with the C-DiGit blot scanner. 
For SNP1, we observed allele-specific binding by nuclear proteins only in the ER
+
 BT474, 
MCF7 and MDA-MB-361 extracts (Figures 3c and S9). The protein-DNA complexes were 
shown to be specific, as demonstrated by increasing amounts of cold self-competitor (Figures 3c, 
S9 and Table S8).  
 
Further EMSAs using competitor DNA or antibody supershifts against predicted transcription 
factors (TFs) suggested four proteins bound to the SNP site including FOXA1, FOXA2, CEBPB 
and OCT1 (Figure S10 and Table S9). To confirm TF binding in vivo, we performed chromatin 
immunoprecipitation (ChIP) in heterozygous BT474 cells as previously described (Table S10).
15
 
When compared to an IgG control antibody, we observed a moderate enrichment in FOXA1 and 
OCT1 binding to DNA overlapping SNP rs10941679, but no difference between alleles in this 
cell line (Figure S11). In addition, Western blot analysis indicated that FOXA1 protein 
expression was restricted to the ER
+
 breast cancer cell lines analysed, whereas OCT1 was more 
widely expressed (Figure S12). FOXA1 is a pioneer factor and master regulator of ER activity 
due to its ability to open local chromatin and recruit ER to target gene promoters.
16
 Notably, 
breast cancer-associated SNPs are enriched for FOXA1 binding
17
 and several studies have linked 
cooperative binding of FOXA1, ER and OCT1 to increased gene transcription.
18; 19
 Consistent 
with our eQTL data, it is tempting to speculate that in specific ER
+
 cell subtypes and/or 
conditions, rs10941679 alters FOXA1 affinity and OCT1 recruitment leading to target gene 
activation. 
 
In conclusion, we have provided evidence for at least three independent causal SNPs with effects 
on the risk of breast cancer at this locus. The minor g-allele of signal 1 SNP rs10941679 
conferred a 15% increased risk of ER
+
 breast cancer and higher expression levels of the MRPS30 
and FGF10 genes and was the most strongly associated SNP with MRPS30 expression in this 
1Mb region. MRPS30 also called PDCD9 (Programmed Cell Death protein 9) encodes a 
mitochondrial ribosomal protein involved in apoptosis.
20
 Although the role of mitochondria in 
apoptosis remains unclear, it is well established that cytochrome c and other pro-apoptotic 
proteins are released during cell death initiation.
20
 Clearly further investigation of the function of 
 11 
this protein is now merited. By contrast, FGF10 is an extensively studied gene with compelling 
data suggesting its involvement in breast tumorigenesis. FGF10 is a member of the fibroblast 
growth factor (FGF) family and encodes a glycoprotein that specifically binds to FGFR2 (splice 
FGFR2IIIb) to control signalling pathways including cell differentiation, proliferation and 
apoptosis.
21
 Variants regulating FGFR2 [MIM 176943] have the strongest association with ER
+
 
breast cancer susceptibility identified to date.
22
 FGF10 is over-expressed in ~10% of human 
breast cancers
23
, and increased levels of FGF10 are highly correlated with proliferation rate of 
breast cancer cell lines and cancer cell invasion.
24; 25
 It signals through multiple downstream 
pathways including MAPK and WNT, and genes such as FGFR2, CCND1 [MIM 168461] and 
TGFB1 [MIM 190180]
21; 24
 all known to play key roles in breast cancer. Therapeutic targeting of 
FGFs and their receptors FGFRs is currently a major area of drug development research and the 
identification of a subgroup of individuals diagnosed with breast cancer with alterations in these 
pathways may open new avenues for personalised medicine and pathway-targeted treatments.  
 
 
SUPPLEMENTARY TEXT 
Supplementary text for online publication is provided in the additional file: 
Ghoussaini_et al_5p12_Supplementary_Text.doc. 
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FIGURE LEGENDS 
Figure 1. Manhattan plot of the 5p12 breast cancer susceptibility locus. SNPs are plotted 
according to their chromosomal position on the x-axis and their overall P values (log10 values, 
likelihood ratio test) from the European BCAC studies (48,155 cases and 43,612 controls) on the 
y-axis. The purple dotted line intersects the y-axis at p=10
-
8 and indicates genome-wide 
significance. Candidate SNPs in signal 1 (rs10941679), signal 2 (38 SNPs) and signal 3 
(rs200229088) are shown as short vertical lines. The locations of annotated genes and putative 
lncRNA transcripts from GENCODE and enhancers predicted in Corradin et al
13
 and Hnisz et 
al
12
 from breast cancer cell lines, are shown in the bottom panels. 
 
Figure 2. Association of rs10941679 with FGF10 and MRPS30 expression in normal breast 
tissues, breast tumors and breast cancer cell lines. FGF10 (a) or MRPS30 (b) expression in 
normal breast (N=116) or breast tumors from NBCS dataset (N=241). SNP genotypes are shown 
on the x-axis and log2-normalized gene expression values on the y-axis. P-values are presented 
before and after correction for multiple testing using FDR as implemented in p.adjust function in 
R. Endogenous FGF10 (Hs00610298_m1) (c) or MRPS30 (Hs00169612_m1) (d) expression 
measured by qPCR in untreated breast cell lines and normalised to GUSB (4326320E). Error bars 
denote SEM (N=3). P-values were determined with a two-tailed t test. **P<0.01, ***P<0.001. 
 
Figure 3. Distal regulation of FGF10 and MRPS30 at the 5p12 risk region. (a) 3C interaction 
profiles between the FGF10/FGF10AS-1 or MRPS30/BRCAT54 bidirectional promoters and the 
putative regulatory element (PRE; grey bar) containing SNP rs10941679. Anchor points are set 
at the promoters. Graphs represent one of three independent experiments (see Figure S5b). Error 
bars denote SD. (b) Luciferase reporter assays following transient transfection of ER
+
 BT474 
breast cancer cell lines. The PRE containing the major SNP allele was cloned downstream of 
target gene promoter-driven luciferase constructs (Ref PRE). The risk g-allele was engineered 
into the constructs and designated by the rs ID. Primers are listed in Table S7. Error bars denote 
95% confidence intervals from three independent experiments. P-values were determined by 2-
way ANOVA followed by Dunnett’s multiple comparisons test (***P<0.001). (c) EMSA for 
oligonucleotides containing SNP rs1094617 with the A=common allele and G=minor allele as 
indicated below the panel, assayed using BT474 nuclear extracts. Primers are listed in Table S8. 
Labels above each lane indicate inclusion of competitor oligonucleotides at 30- and 100-fold 
molar excess, respectively: (-) no competitor and control denotes a non-specific competitor. A 
red arrowhead shows a band of different mobility detected between the common and minor 
alleles. 
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Table 1. Associations of the top SNPs from each signal with overall breast cancer risk and breast cancer stratified by ER 
status. 
Common (Com) and Minor (Min) alleles, Minor Allele Frequncy (MAF), Per-allele odds ratios (OR), 95% Confidence intervals 
(95%CI) and 1 degree of freedom Significance levels (P) for overall breast cancer are indicated in European and Asian case-control 
studies, and separately for ER
+
 and ER
-
 disease.  
 
Europeans 
Sig SNP Com Min MAF
* 
OR_overall  
95% CI 
P_overall  Conditional 
p-value 
OR ER-  P_ER- OR_ER+  P_ER+  
1 rs10941679 A G 0.27 1.12 
[1.10-1.14] 
2.55E-26 6.55E-24 1.04 
[1-1.08] 
0.059 1.15 
[1.13-1.18] 
8.35E-30 
2 rs6864776 G A 0.23 1.04 
[1.02-1.06] 
7.84E-04 1.44E-12 1.10 
[1.05-1.14] 
2.5E-05 1.02 
[0.99-1.05] 
0.08 
3 rs200229088 TTG T 0.31 1.09 
[1.07-1.12] 
2.28E-12 1.12E-05 1.03 
[0.99-1.09] 
0.11 1.12 
[1.09-1.15] 
7.51E-14 
Asians 
1 rs10941679 A G 0.50 1.09 
[1.04-1.15] 
9.12E-04 0.0859 1.03 
[0.95-1.11] 
0.53 1.11 
[1.04-1.18] 
1.32E-03 
2 rs6864776 G A 0.32 0.94 
[0.89-1.00] 
3.47E-02 0.8901 0.95 
[0.87-1.04] 
0.28 0.94 
[0.89-1.00] 
6.24E-02 
3 rs200229088 TTG T 0.37 1.09 
[1.02-1.15] 
6.52E-03 0.9149 1.04 
[0.95-1.14] 
0.43 1.08 
[1.00-1.16] 
3.65E-02 
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Table 2. Haplotype analysis across the BCAC studies. Each haplotype was compared to the ancestral haplotype carrying the common 
alleles of signal 1 SNP rs10941679, signal 2 SNP rs6864776 and signal 3 SNP rs200229088 (haplotype A).  
 
Haplotypes rs10941679 
Signal 1 
rs6864776 
Signal 2 
rs200229088 
Signal 3 
Haplotype 
frequency 
OR P-value 
A 1 1 1 0.395440 _ _ 
B 1 1 2 0.120099 1.06[1.02-1.10] 1.49E-03 
C 1 2 1 0.199599 1.10 [1.06-1.13] 7.76E-11 
D 1 2 2 0.018665 1.15 [1.04-1.27] 5.03E-03 
E 2 1 1 0.098169 1.14 [1.09-1.19] 1.45E-11 
F 2 1 2 0.154525 1.20 [1.16-1.24] 2.72E-30 
G 2 2 1 0.004248 0.91 [0.72-1.15] 4.15E-01 
H 2 2 2 0.009253 1.28 [1.10-1.48] 1.14E-03 
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Supplementary Figure 1. Associations of SNP rs10941679 with expression of candidate target genes. (a) 183 
normal breast samples from the GTEx database, (b) FGF10 or (c) MRPS30 in normal breast TCGA (N=93) and breast 
tumours TCGA (N=765). The x-axis of each plot corresponds to the three observed SNP genotypes and the y-axis 
represents log2-normalized gene expression values. P-values in the GTEx datasets are pre-corrected for multiple testing. 
P-values in the TCGA datasets are presented before and after correction for multiple testing using FDR as implemented in 
p.adjust function in R. 
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Supplementary Figure 2. Location of putative noncoding RNAs close to the top risk SNPs. The top risk SNPs from 
each signal are shown as small horizontal lines and labelled. Green boxes represent putative noncoding RNAs.  
 
  
  
 
Supplementary Figure 3. Putative noncoding RNA expression measured by qPCR in untreated breast cell lines and 
normalised to TBP. Error bars denote SEM (N=3).  
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Supplementary Figure 4. Genomic region (chr5:44276112-44866764) showing chromatin 
state annotations called by Roadmap Epigenomics Project Chromatin Hidden Markov 
Modelling (Imputed ChromHMM) relative to GENCODE V19 gene models. The 25 states of 
chromatin segmentation depicted as colors along the genomic axis are described in the key. 
The position of top risk SNPs for signals 1-3 are shown by the vertical black lines. 
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Supplementary Figure 5. Chromatin interactions at 5p12 in breast cancer cell lines. (a) Physical map of the region 
interrogated by 3C. 3C interaction profiles between the FGF10/FGF10AS-1, MRPS30/BRCAT54 or HCN1 promoters and 
the putative regulatory element (PRE, grey bars) containing SNP rs10941679 in (b) ER+/PR+ MCF7 and BT474, (c) 
ER+/PR- MDA-MB-361 or ER-/PR- MDA-MB-231 breast cancer cell lines and (d) ER- Bre80 normal breast cells. 3C 
libraries were generated with EcoRI, with the anchor points set at the promoters. Error bars denote SD.   
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Supplementary Figure 6. DNA sequencing to confirm chromatin interactions. Chromatogram of 3C products 
amplified between the (a) FGF10 or (b) MRPS30 promoters and the 5p12 putative regulatory element (PRE) containing 
SNP rs10941679. 
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Supplementary Figure 7. SNP rs10941679 does not influence chromatin looping between the PRE and FGF10 or 
MRPS30 promoters. 3C followed by sequencing for the rs10941679-containing region in heterozygous BT474 ER+ 
breast cancer cells. 
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Supplementary Figure 8. Luciferase reporter assays in ER+ MCF7 and ER- Bre80 breast cell lines. The putative 
regulatory element containing the major SNP allele was cloned downstream of target gene promoter-driven luciferase 
constructs (Ref PRE). The minor SNP allele was engineered into the constructs and is designated by the rs ID. Error bars 
denote 95% confidence intervals from three independent experiments. P-values were determined by 2-way ANOVA 
followed by Dunnett’s multiple comparisons test. **P<0.01, ***P<0.001. 
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Supplementary Figure 9. EMSAs for oligonucleotides containing SNP rs10941679. The A=common allele and 
G=minor allele as indicated below the panel, assayed using (a) ER+/PR- MDA-MB-361, ER+/PR+ MCF7 and (b) ER-/PR- 
MDA-MB-231 and Hs578T nuclear extracts. Primers are listed in Table S8. Labels above each lane indicate inclusion of 
competitor oligonucleotides at 100-fold molar excess, respectively: (-) no competitor and control denotes a non-specific 
competitor. Red arrowheads show bands of different mobility detected between the A and G alleles. 
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Supplementary Figure 10. Competition EMSAs for SNP rs10941679 to identify candidate nuclear proteins. 
Competitor oligonucleotides for predicted transcription factors (100-fold molar excess) were incubated with ER+ BT474 
nuclear extracts (competitor sequences are listed in Table S9). Red arrowheads indicate bands that were competed for 
complex formation on either the (a) common or (b) minor alleles. (c) EMSA-supershift using the common DNA duplex and 
2 µg of polyclonal antibody against FOXA1 (ab5089, abcam), FOXA2 (sc-20692, Santa Cruz Biotechnology), CEBPB (sc-
150) or OCT1 (sc-232) with BT474 nuclear extracts. Rabbit IgG (sc-2027) was used as a negative control. The red 
arrowhead denotes supershifted complexes.  
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Supplementary Figure 11. FOXA1 and OCT1 binding in vivo. ChIP-qPCR results against (a) FOXA1, (b) OCT1, (c) 
FOXA2 or (d) CEBPB in heterozygous BT474 breast cancer cells. Error bars denote SD (N=2). A region within the second 
intron of ESR1 served as a negative (Neg) control. P-values were determined by two-tailed t-t test. **P<0.01, ***P<0.001. 
(e) Sanger sequencing of the PCR fragment generated using primers flanking SNP rs10941679 following ChIP-qPCR. 
Primers are listed in Table S10. 
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Supplementary Figure 12. Western blot analysis of FOXA1 and OCT1 protein expression in breast cancer cell 
lines. Actin (Sigma A2066) served as a loading control. 
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 Supplementary Table 1. Strongest Associated SNPs (N=461 P<10-4) with overall breast cancer risk from 41 European 
BCAC studies (n=104,660). * Type refers to either genotyped or imputed SNPs.  
 
SNP position Ref Alt EAF OR 
overall 
Pvalue 
overall 
OR ER+ Pvalue 
ER+ 
OR 
ER- 
Pvalue 
ER- 
Type R2 
rs10941679 44706498 A G 0.27 1.12 2.55E-26 1.15 2.44E-29 1.04 0.08 Gen 0.99 
rs10462082 44800917 A C 0.50 1.1 9.11E-22 1.11 3.40E-20 1.06 0.00 Imp 0.95 
c5_pos44911206 44875449 A G 0.48 0.91 1.67E-21 0.90 3.28E-21 0.95 0.01 Gen 1.00 
rs6451770 44691395 T G 0.39 1.1 2.50E-21 1.13 4.76E-25 1.01 0.59 Gen 1.00 
rs7716600 44875005 A C 0.77 0.9 4.13E-21 0.87 3.17E-24 0.96 0.09 Gen 1.00 
rs930395 44822458 G A 0.23 1.11 7.58E-21 1.14 4.87E-24 1.04 0.08 Gen 1.00 
rs13185555 44690964 G A 0.39 1.1 7.59E-21 1.13 5.36E-25 1.01 0.75 Imp 0.98 
rs76514876 44673354 A C 0.41 1.1 4.91E-20 1.12 5.39E-23 1.01 0.72 Imp 0.98 
rs4463188 44642670 T C 0.41 1.09 5.35E-20 1.12 8.29E-23 1.00 0.80 Gen 1.00 
rs4321755 44646195 C T 0.41 1.09 6.44E-20 1.12 6.75E-23 1.00 0.81 Gen 1.00 
rs4339357 44670741 T C 0.40 1.1 6.64E-20 1.12 9.24E-23 1.01 0.56 Imp 0.97 
rs4479849 44644006 G A 0.41 1.09 6.93E-20 1.12 4.92E-23 1.00 0.85 Gen 1.00 
rs12187196 44683819 A C 0.41 1.09 7.47E-20 1.12 8.48E-23 1.01 0.62 Gen 1.00 
rs36068815 44645998 T C 0.41 1.09 7.80E-20 1.12 5.15E-23 1.00 0.84 Gen 1.00 
rs13155752 44680687 A C 0.41 1.09 1.65E-19 1.12 7.46E-23 1.01 0.71 Imp 0.98 
rs13156283 44680758 G C 0.41 1.09 1.66E-19 1.12 7.48E-23 1.01 0.71 Imp 0.98 
rs4492118 44646625 G A 0.41 1.09 1.86E-19 1.12 1.98E-22 1.01 0.79 Gen 1.00 
rs7735881 44650176 A G 0.41 1.09 1.90E-19 1.12 1.15E-22 1.00 0.82 Gen 1.00 
rs12516900 44644495 A G 0.41 1.09 2.27E-19 1.12 2.34E-22 1.01 0.78 Gen 1.00 
rs6861560 44708378 C G 0.41 1.09 2.31E-19 1.12 7.82E-23 1.01 0.71 Imp 0.98 
rs1821936 44699482 A C 0.41 1.09 2.42E-19 1.12 1.30E-22 1.01 0.67 Imp 0.99 
chr5:44648592:I 44648592 C CTAT 0.41 1.09 2.42E-19 1.12 2.22E-22 1.01 0.76 Imp 0.98 
chr5:44645330:D 44645330 AG A 0.40 1.1 2.50E-19 1.12 3.61E-22 1.01 0.77 Imp 0.95 
rs6874055 44666965 T A 0.41 1.09 2.51E-19 1.12 1.70E-22 1.01 0.75 Imp 0.99 
rs12522626 44685698 G T 0.41 1.09 2.67E-19 1.12 1.73E-22 1.01 0.69 Gen 1.00 
rs10805686 44662128 T C 0.41 1.09 2.95E-19 1.12 2.24E-22 1.01 0.76 Gen 1.00 
rs6890556 44648666 C G 0.41 1.09 3.01E-19 1.12 3.17E-22 1.01 0.76 Gen 1.00 
rs2165010 44706780 A C 0.41 1.09 3.12E-19 1.12 1.68E-22 1.01 0.68 Imp 0.99 
rs13176502 44697908 T C 0.41 1.09 3.36E-19 1.12 2.17E-22 1.01 0.66 Imp 0.99 
rs714130 44701418 T C 0.41 1.09 3.55E-19 1.12 2.03E-22 1.01 0.68 Gen 1.00 
rs1438825 44706931 G A 0.41 1.09 3.58E-19 1.12 1.63E-22 1.01 0.72 Gen 1.00 
rs10941677 44662399 G A 0.41 1.09 3.64E-19 1.12 2.24E-22 1.01 0.77 Gen 1.00 
rs1371027 44699857 T C 0.41 1.09 3.65E-19 1.12 1.90E-22 1.01 0.69 Gen 1.00 
rs2218081 44705140 C T 0.41 1.09 3.76E-19 1.12 1.50E-22 1.01 0.74 Gen 1.00 
rs4415084 44662515 C T 0.41 1.09 3.81E-19 1.12 2.67E-22 1.01 0.78 Gen 1.00 
 rs1898701 44695429 A G 0.41 1.09 3.87E-19 1.12 2.53E-22 1.01 0.67 Imp 0.99 
rs2165009 44697916 C T 0.41 1.09 4.09E-19 1.12 1.53E-22 1.01 0.72 Gen 0.99 
rs4415085 44662959 C G 0.41 1.09 4.21E-19 1.12 2.45E-22 1.00 0.82 Gen 1.00 
rs6871484 44676305 T C 0.41 1.09 4.24E-19 1.12 2.26E-22 1.01 0.75 Imp 0.99 
rs920329 44702507 T C 0.41 1.09 4.54E-19 1.12 1.71E-22 1.01 0.75 Gen 1.00 
rs6863598 44668623 C T 0.41 1.09 4.62E-19 1.12 2.67E-22 1.01 0.76 Imp 0.98 
rs4419600 44678534 T G 0.41 1.09 4.72E-19 1.12 4.27E-22 1.01 0.74 Gen 1.00 
rs34762678 44705514 T C 0.41 1.09 4.75E-19 1.12 2.22E-22 1.01 0.67 Gen 1.00 
rs4571480 44687188 C T 0.41 1.09 4.85E-19 1.12 1.64E-22 1.01 0.77 Gen 1.00 
rs13156930 44698035 G C 0.41 1.09 4.92E-19 1.12 1.76E-22 1.01 0.75 Gen 1.00 
c5_pos44711954 44676197 C T 0.41 1.09 5.20E-19 1.12 3.06E-22 1.00 0.80 Gen 1.00 
chr5:44637587:I 44637587 T TC 0.40 1.09 5.28E-19 1.12 2.86E-22 1.00 0.87 Imp 0.97 
chr5:44929230:D 44929230 ATAATAT 
ATATATT 
A 0.60 0.91 5.60E-19 0.89 4.32E-21 0.98 0.44 Imp 0.92 
rs10462079 44700110 G T 0.41 1.09 5.77E-19 1.12 3.09E-22 1.01 0.69 Gen 0.99 
chr5:44678911:D 44678911 TA T 0.40 1.09 5.83E-19 1.12 3.22E-22 1.01 0.79 Imp 0.97 
rs2218080 44714330 T C 0.42 1.09 5.99E-19 1.12 2.50E-22 1.01 0.76 Imp 0.96 
rs2013513 44702306 G A 0.41 1.09 6.02E-19 1.12 3.39E-22 1.01 0.68 Imp 0.99 
rs13179137 44702692 C T 0.41 1.09 6.55E-19 1.12 2.82E-22 1.01 0.69 Gen 1.00 
rs7720551 44664477 C T 0.41 1.09 7.05E-19 1.12 4.87E-22 1.00 0.81 Imp 0.99 
rs10941678 44672783 C A 0.38 1.1 7.18E-19 1.13 7.22E-22 1.00 0.98 Imp 0.89 
rs4607355 44868070 A G 0.52 0.91 7.56E-19 0.89 3.46E-20 0.97 0.12 Imp 0.84 
rs144629423 44669403 G T 0.41 1.09 8.10E-19 1.12 4.28E-22 1.01 0.75 Imp 0.97 
rs6884702 44682589 A G 0.40 1.09 8.55E-19 1.12 3.18E-22 1.01 0.75 Imp 0.99 
rs7723539 44660210 G C 0.41 1.09 8.60E-19 1.12 5.63E-22 1.00 0.84 Imp 0.99 
rs10805685 44661958 C G 0.41 1.09 9.02E-19 1.12 5.83E-22 1.00 0.84 Imp 0.99 
rs4571481 44687433 C T 0.39 1.09 9.77E-19 1.11 4.21E-21 1.03 0.19 Gen 0.95 
rs12515012 44694535 G A 0.40 1.09 9.84E-19 1.12 4.89E-22 1.01 0.75 Imp 0.98 
rs181516187 44672104 C T 0.40 1.09 1.11E-18 1.12 6.79E-22 1.00 0.82 Imp 0.97 
rs16901937 44709141 A G 0.41 1.09 1.71E-18 1.12 7.12E-22 1.01 0.79 Gen 1.00 
rs7701466 44663137 C T 0.40 1.09 3.42E-18 1.12 1.08E-21 1.00 1.00 Imp 0.97 
rs11949847 44752169 A G 0.42 1.09 3.92E-18 1.11 1.08E-20 1.00 0.81 Gen 0.99 
c5_pos44685154 44649397 A C 0.38 1.09 4.42E-18 1.11 1.23E-20 1.02 0.32 Gen 0.98 
rs56248730 44681267 A G 0.38 1.09 4.64E-18 1.12 9.44E-21 1.02 0.32 Imp 0.98 
c5_pos44720000 44684243 A G 0.38 1.09 4.65E-18 1.12 8.11E-21 1.02 0.32 Gen 1.00 
rs6867533 44827292 G T 0.40 1.09 5.17E-18 1.11 2.05E-20 1.00 0.84 Gen 0.96 
rs994793 44743247 A G 0.42 1.09 5.41E-18 1.11 1.04E-20 1.00 0.82 Gen 1.00 
rs920328 44699051 G A 0.38 1.09 6.04E-18 1.12 7.48E-21 1.02 0.31 Gen 1.00 
rs11746980 44777878 G A 0.42 1.09 6.64E-18 1.11 2.04E-20 1.00 0.80 Gen 1.00 
rs2330572 44740989 A C 0.42 1.09 7.56E-18 1.11 1.25E-20 1.00 0.84 Gen 1.00 
rs7737491 44790842 A G 0.37 1.09 8.66E-18 1.11 4.58E-19 1.03 0.20 Imp 0.96 
rs10447145 44689796 T G 0.38 1.09 8.76E-18 1.11 1.33E-20 1.02 0.34 Imp 0.98 
 rs145342568 44672237 A G 0.39 1.09 1.00E-17 1.12 8.13E-21 1.01 0.69 Imp 0.91 
rs13160259 44828964 G C 0.42 1.09 1.17E-17 1.11 5.45E-20 1.01 0.77 Imp 0.98 
rs10072259 44834791 T C 0.61 0.92 1.22E-17 0.90 1.39E-19 0.98 0.35 Imp 0.98 
rs10512865 44823367 C T 0.41 1.09 1.27E-17 1.11 6.61E-20 1.01 0.77 Imp 0.99 
rs11958808 44945090 G C 0.41 1.09 1.36E-17 1.11 1.25E-19 1.01 0.76 Gen 1.00 
rs4866922 44932505 C G 0.59 0.92 1.41E-17 0.90 1.11E-19 0.99 0.72 Imp 0.99 
chr5:44837254:I 44837254 T TA 0.58 0.92 1.43E-17 0.90 7.54E-20 0.99 0.77 Imp 0.99 
rs1048758 44828594 G A 0.41 1.09 1.43E-17 1.11 6.71E-20 1.00 0.80 Gen 1.00 
rs1371023 44846575 C T 0.59 0.92 1.52E-17 0.90 8.79E-20 1.00 0.79 Gen 1.00 
rs10054773 44930234 C G 0.59 0.92 1.54E-17 0.90 1.30E-19 0.99 0.71 Imp 0.98 
rs10044096 44927365 A C 0.59 0.92 1.55E-17 0.90 1.49E-19 0.99 0.71 Imp 0.99 
rs7716571 44816984 G A 0.42 1.09 1.62E-17 1.11 1.20E-19 1.01 0.78 Gen 0.96 
chr5:44884873:D 44884873 TAAAC T 0.58 0.92 1.73E-17 0.90 1.36E-19 0.99 0.73 Imp 0.98 
rs2118764 44787723 C T 0.41 1.09 1.77E-17 1.11 1.40E-19 1.00 0.80 Imp 0.98 
rs10064434 44834702 G A 0.58 0.92 1.81E-17 0.90 7.93E-20 1.00 0.81 Imp 0.98 
rs930396 44856451 T G 0.59 0.92 1.89E-17 0.90 1.58E-19 0.99 0.79 Gen 1.00 
rs7380559 44837010 A T 0.59 0.92 1.91E-17 0.90 1.02E-19 1.00 0.80 Gen 1.00 
rs1821934 44789172 T C 0.41 1.09 1.91E-17 1.11 1.63E-19 1.01 0.74 Imp 0.98 
rs7711697 44780403 A T 0.41 1.09 1.95E-17 1.11 1.24E-19 1.00 0.82 Gen 1.00 
rs7711136 44823079 G C 0.41 1.09 1.96E-17 1.11 1.10E-19 1.00 0.79 Gen 0.99 
rs1438820 44797770 G A 0.41 1.09 2.03E-17 1.11 1.20E-19 1.00 0.84 Gen 1.00 
rs4866923 44932641 A C 0.58 0.92 2.07E-17 0.90 2.19E-19 0.99 0.74 Imp 0.97 
rs6896417 44802638 A G 0.41 1.09 2.15E-17 1.11 1.56E-19 1.00 0.84 Gen 1.00 
rs1061310 44820850 G C 0.41 1.09 2.15E-17 1.11 1.16E-19 1.01 0.79 Gen 1.00 
rs1438821 44858451 G A 0.59 0.92 2.17E-17 0.90 1.82E-19 1.00 0.80 Gen 1.00 
rs13177711 44796962 A T 0.41 1.09 2.23E-17 1.11 1.69E-19 1.00 0.83 Gen 0.99 
rs4629607 44857467 G T 0.58 0.92 2.23E-17 0.90 6.97E-18 0.97 0.11 Imp 0.90 
rs13159598 44805926 A G 0.41 1.09 2.27E-17 1.11 1.61E-19 1.00 0.83 Gen 1.00 
rs7730841 44823134 T C 0.42 1.09 2.32E-17 1.11 1.24E-19 1.00 0.80 Gen 0.98 
rs13362132 44858260 T G 0.59 0.92 2.54E-17 0.90 2.03E-19 1.00 0.79 Gen 1.00 
rs10043344 44926518 A T 0.59 0.92 2.57E-17 0.90 1.50E-19 0.99 0.76 Gen 1.00 
rs187822318 44671468 C G 0.35 1.1 2.71E-17 1.12 2.72E-19 1.02 0.28 Imp 0.84 
rs7720787 44817309 G A 0.41 1.09 2.88E-17 1.11 1.52E-19 1.00 0.82 Gen 1.00 
rs7705343 44879577 G A 0.59 0.92 3.06E-17 0.90 2.70E-19 0.99 0.79 Gen 1.00 
rs149708574 44825919 T A 0.30 1.1 3.10E-17 1.12 2.35E-18 1.04 0.07 Imp 0.84 
rs2877172 44790567 A G 0.41 1.09 3.13E-17 1.11 2.26E-19 1.00 0.83 Imp 0.97 
rs4518409 44870852 T C 0.59 0.92 3.18E-17 0.90 2.75E-19 1.00 0.83 Gen 1.00 
rs10077814 44916789 C T 0.59 0.92 3.39E-17 0.90 1.88E-19 1.00 0.80 Gen 1.00 
rs4329028 44872353 T A 0.59 0.92 3.64E-17 0.90 4.23E-19 0.99 0.76 Gen 1.00 
chr5:44921964:I 44921964 A AT 0.59 0.92 4.14E-17 0.90 3.42E-19 0.99 0.78 Imp 0.96 
c5_pos44933593 44897836 T C 0.59 0.92 4.45E-17 0.90 2.78E-19 0.99 0.78 Gen 0.99 
 rs9292915 44871657 C T 0.59 0.92 4.49E-17 0.90 4.55E-19 0.99 0.78 Gen 1.00 
rs9292913 44870879 G A 0.59 0.92 4.63E-17 0.90 4.50E-19 1.00 0.80 Gen 1.00 
rs4412123 44876288 T C 0.59 0.92 4.79E-17 0.90 4.15E-19 1.00 0.86 Gen 1.00 
rs9790896 44900091 G A 0.59 0.92 5.21E-17 0.90 2.76E-19 1.00 0.86 Gen 1.00 
chr5:44818855:D 44818855 CCAA 
ATGGT 
C 0.38 1.09 5.37E-17 1.11 1.48E-18 1.02 0.26 Imp 0.99 
rs9790879 44899885 C T 0.59 0.92 5.65E-17 0.90 2.82E-19 1.00 0.86 Gen 1.00 
rs11957920 44905086 T C 0.59 0.92 5.72E-17 0.90 4.80E-19 1.00 0.86 Gen 1.00 
rs10070339 44907882 G A 0.59 0.92 6.40E-17 0.90 4.39E-19 1.00 0.90 Gen 1.00 
rs7726586 44848822 C T 0.62 0.92 9.03E-17 0.90 1.89E-18 0.98 0.33 Gen 1.00 
rs13154781 44775027 C T 0.39 1.09 9.35E-17 1.11 9.73E-19 1.02 0.35 Imp 0.99 
rs1438827 44751956 C A 0.39 1.09 9.41E-17 1.11 7.00E-19 1.02 0.35 Gen 1.00 
rs7712949 44770345 C T 0.39 1.09 9.90E-17 1.11 7.94E-19 1.02 0.37 Gen 1.00 
chr5:44810239:D 44810239 TG T 0.41 1.09 1.01E-16 1.11 6.06E-19 1.01 0.74 Imp 0.96 
rs7708213 44848401 T C 0.62 0.92 1.03E-16 0.90 2.52E-18 0.98 0.30 Gen 1.00 
rs34237302 44852862 C A 0.61 0.92 1.04E-16 0.90 2.61E-18 0.98 0.29 Gen 0.99 
rs4440370 44853352 A G 0.62 0.92 1.10E-16 0.90 2.63E-18 0.98 0.31 Gen 1.00 
rs11747159 44737710 C T 0.39 1.09 1.12E-16 1.11 1.12E-18 1.02 0.34 Gen 1.00 
rs4492119 44855614 A G 0.61 0.92 1.37E-16 0.90 2.83E-18 0.98 0.33 Gen 0.98 
rs1371022 44847992 T A 0.62 0.92 1.42E-16 0.90 3.56E-18 0.98 0.32 Gen 1.00 
rs987394 44846378 A G 0.62 0.92 1.49E-16 0.90 3.64E-18 0.98 0.31 Gen 1.00 
rs10462081 44800665 G A 0.38 1.09 1.58E-16 1.11 4.22E-18 1.02 0.33 Gen 1.00 
rs1438819 44797846 T A 0.38 1.09 1.60E-16 1.11 4.54E-18 1.02 0.34 Gen 1.00 
rs7715731 44846844 A C 0.62 0.92 1.69E-16 0.90 3.01E-18 0.98 0.33 Gen 1.00 
rs1371025 44834233 G A 0.62 0.92 1.70E-16 0.90 3.46E-18 0.98 0.32 Gen 0.99 
rs1866406 44809945 G C 0.39 1.09 1.74E-16 1.11 4.31E-18 1.02 0.32 Gen 0.99 
rs9637797 44818181 A G 0.39 1.09 1.74E-16 1.11 3.90E-18 1.02 0.32 Gen 1.00 
rs930394 44822617 G A 0.38 1.09 1.83E-16 1.11 3.68E-18 1.02 0.32 Gen 1.00 
rs3761650 44808356 G A 0.38 1.09 1.83E-16 1.11 4.39E-18 1.02 0.33 Gen 1.00 
rs6451781 44860506 T C 0.61 0.92 1.86E-16 0.90 6.29E-18 0.98 0.31 Gen 1.00 
rs10462080 44799052 C A 0.38 1.09 1.90E-16 1.11 5.95E-18 1.02 0.34 Imp 0.98 
rs71610376 44825023 G C 0.38 1.09 1.92E-16 1.11 3.97E-18 1.02 0.33 Imp 0.99 
rs12517690 44939293 G A 0.39 1.09 1.93E-16 1.11 5.48E-18 1.02 0.32 Gen 1.00 
chr5:44816067:D 44816067 TAAAAG T 0.38 1.09 1.96E-16 1.11 4.43E-18 1.02 0.33 Imp 0.99 
rs727305 44796042 T C 0.39 1.09 1.97E-16 1.11 4.67E-18 1.02 0.35 Gen 0.99 
rs7703497 44857028 A G 0.61 0.92 1.97E-16 0.90 5.87E-18 0.98 0.34 Gen 1.00 
rs4457089 44821736 C T 0.38 1.09 2.02E-16 1.11 4.19E-18 1.02 0.32 Gen 1.00 
rs1371024 44843590 C T 0.61 0.92 2.04E-16 0.90 4.26E-18 0.98 0.32 Gen 1.00 
rs727304 44796290 G A 0.38 1.09 2.05E-16 1.11 5.92E-18 1.02 0.34 Gen 1.00 
rs10038562 44832226 C T 0.61 0.92 2.05E-16 0.90 4.15E-18 0.98 0.32 Gen 0.99 
rs13174122 44810740 T C 0.39 1.09 2.06E-16 1.11 4.57E-18 1.02 0.32 Gen 0.99 
rs7703059 44826436 G A 0.38 1.09 2.06E-16 1.11 4.34E-18 1.02 0.34 Imp 0.99 
 rs2165008 44821679 G A 0.38 1.09 2.08E-16 1.11 4.35E-18 1.02 0.32 Gen 1.00 
rs7717459 44804525 C T 0.38 1.09 2.12E-16 1.11 5.66E-18 1.02 0.34 Gen 1.00 
rs4298259 44920711 G A 0.61 0.92 2.12E-16 0.90 4.29E-18 0.98 0.33 Gen 1.00 
rs11746506 44812566 C T 0.38 1.09 2.13E-16 1.11 4.36E-18 1.02 0.32 Gen 1.00 
rs12513749 44828203 G A 0.39 1.09 2.16E-16 1.11 4.46E-18 1.02 0.34 Imp 0.99 
rs13189120 44822283 A T 0.39 1.09 2.17E-16 1.11 4.55E-18 1.02 0.32 Gen 1.00 
rs6868232 44827680 G C 0.38 1.09 2.18E-16 1.11 4.19E-18 1.02 0.34 Imp 0.99 
rs16901989 44837129 C T 0.61 0.92 2.18E-16 0.90 4.61E-18 0.98 0.32 Gen 1.00 
rs13155698 44828681 A C 0.39 1.09 2.18E-16 1.11 3.97E-18 1.02 0.33 Gen 1.00 
rs6896350 44832571 C A 0.61 0.92 2.19E-16 0.90 4.25E-18 0.98 0.33 Gen 1.00 
rs1438822 44859172 C G 0.61 0.92 2.21E-16 0.90 7.25E-18 0.98 0.32 Gen 1.00 
rs729599 44842260 G A 0.62 0.92 2.23E-16 0.90 3.96E-18 0.98 0.33 Imp 0.99 
rs6451772 44785763 A C 0.39 1.09 2.24E-16 1.11 6.13E-18 1.02 0.37 Imp 0.98 
rs6872254 44803784 C T 0.39 1.09 2.28E-16 1.11 6.90E-18 1.02 0.34 Gen 0.99 
rs1837286 44858741 C T 0.62 0.92 2.28E-16 0.90 6.49E-18 0.98 0.32 Imp 0.99 
rs4373287 44862884 G T 0.61 0.92 2.28E-16 0.90 7.68E-18 0.98 0.33 Imp 0.99 
rs11741772 44814597 A C 0.38 1.09 2.29E-16 1.11 5.23E-18 1.02 0.33 Imp 0.99 
rs3761648 44808079 A G 0.38 1.09 2.31E-16 1.11 5.47E-18 1.02 0.34 Imp 0.99 
rs16901964 44783255 C T 0.38 1.09 2.33E-16 1.11 5.86E-18 1.02 0.35 Gen 1.00 
rs12651949 44798112 C T 0.38 1.09 2.33E-16 1.11 6.20E-18 1.02 0.34 Gen 1.00 
rs10462083 44806737 T G 0.38 1.09 2.33E-16 1.11 5.65E-18 1.02 0.35 Imp 0.99 
rs4596389 44836556 A C 0.62 0.92 2.35E-16 0.90 3.59E-18 0.98 0.33 Gen 1.00 
rs969679 44804052 T C 0.38 1.09 2.35E-16 1.11 5.95E-18 1.02 0.34 Imp 0.99 
rs16901990 44842740 A C 0.62 0.92 2.35E-16 0.90 3.54E-18 0.98 0.33 Gen 1.00 
rs7707315 44918805 T C 0.61 0.92 2.38E-16 0.90 4.48E-18 0.98 0.35 Gen 1.00 
rs16901965 44783358 G A 0.38 1.09 2.39E-16 1.11 5.51E-18 1.02 0.35 Gen 1.00 
rs3761649 44808164 T C 0.38 1.09 2.40E-16 1.11 5.60E-18 1.02 0.34 Imp 0.99 
rs16901963 44783102 T A 0.39 1.09 2.40E-16 1.11 5.55E-18 1.02 0.35 Gen 1.00 
rs6451775 44836788 G A 0.62 0.92 2.41E-16 0.90 4.60E-18 0.98 0.33 Imp 0.99 
rs12518851 44828231 A G 0.38 1.09 2.44E-16 1.11 4.45E-18 1.02 0.34 Imp 0.99 
rs9637796 44817919 G A 0.38 1.09 2.45E-16 1.11 5.69E-18 1.02 0.33 Imp 0.99 
rs7736952 44790379 C T 0.39 1.09 2.49E-16 1.11 6.96E-18 1.02 0.35 Imp 0.99 
rs6451783 44918293 G A 0.61 0.92 2.51E-16 0.90 4.43E-18 0.98 0.35 Gen 1.00 
rs6893319 44863729 T G 0.62 0.92 2.53E-16 0.90 7.70E-18 0.98 0.34 Imp 0.99 
rs2083243 44840147 C T 0.62 0.92 2.55E-16 0.90 4.35E-18 0.98 0.33 Imp 0.99 
rs12188871 44814004 G A 0.39 1.09 2.55E-16 1.11 5.73E-18 1.02 0.32 Gen 1.00 
rs13185174 44791791 G A 0.38 1.09 2.56E-16 1.11 5.98E-18 1.02 0.36 Imp 0.98 
rs10041518 44927406 T C 0.61 0.92 2.57E-16 0.90 6.23E-18 0.98 0.34 Gen 1.00 
rs2330620 44839822 G A 0.62 0.92 2.58E-16 0.90 4.62E-18 0.98 0.33 Imp 0.99 
rs4604199 44855716 T C 0.62 0.92 2.59E-16 0.90 6.78E-18 0.98 0.34 Imp 0.99 
rs4605791 44855712 T G 0.62 0.92 2.60E-16 0.90 6.78E-18 0.98 0.34 Imp 0.99 
 rs1837285 44858490 T G 0.62 0.92 2.60E-16 0.90 6.52E-18 0.98 0.33 Imp 0.99 
rs3747479 44809162 G C 0.39 1.09 2.60E-16 1.11 5.48E-18 1.02 0.34 Gen 1.00 
rs6871052 44863317 C T 0.62 0.92 2.63E-16 0.90 7.44E-18 0.98 0.34 Gen 1.00 
rs6451784 44922331 A G 0.58 0.92 2.63E-16 0.90 3.17E-18 0.98 0.34 Imp 0.90 
rs7728431 44922679 T C 0.61 0.92 2.65E-16 0.90 5.40E-18 0.98 0.34 Gen 1.00 
rs4566804 44855739 T C 0.62 0.92 2.66E-16 0.90 6.87E-18 0.98 0.34 Imp 0.99 
rs7736092 44920995 C T 0.61 0.92 2.66E-16 0.90 5.15E-18 0.98 0.33 Gen 1.00 
rs10064437 44834721 G C 0.61 0.92 2.69E-16 0.90 3.66E-18 0.98 0.37 Imp 0.98 
rs10070928 44888557 C G 0.60 0.92 2.72E-16 0.91 9.63E-18 0.98 0.31 Gen 0.96 
rs7710952 44785791 C T 0.38 1.09 2.74E-16 1.11 7.59E-18 1.02 0.35 Imp 0.99 
rs7710978 44785864 A G 0.38 1.09 2.75E-16 1.11 7.62E-18 1.02 0.35 Imp 0.99 
rs10053247 44863959 C T 0.62 0.92 2.78E-16 0.90 8.60E-18 0.98 0.34 Imp 0.99 
rs12656984 44824702 A G 0.38 1.09 2.79E-16 1.11 6.67E-18 1.02 0.32 Imp 0.98 
rs7703618 44914579 G A 0.61 0.92 2.83E-16 0.90 7.58E-18 0.98 0.34 Gen 1.00 
rs10044321 44890760 G A 0.61 0.92 2.85E-16 0.91 8.30E-18 0.98 0.35 Imp 0.99 
rs10073945 44932134 A G 0.61 0.92 2.86E-16 0.90 6.86E-18 0.98 0.35 Imp 0.99 
chr5:44916609:D 44916609 GT G 0.63 0.92 2.92E-16 0.90 4.50E-18 0.98 0.33 Imp 0.96 
rs13179835 44908703 G A 0.61 0.92 2.94E-16 0.90 5.90E-18 0.99 0.45 Imp 0.97 
rs6871820 44919557 T C 0.61 0.92 2.99E-16 0.90 6.36E-18 0.98 0.33 Gen 0.99 
rs10038554 44927107 G A 0.61 0.92 2.99E-16 0.90 6.52E-18 0.98 0.34 Gen 1.00 
rs34325259 44936860 G T 0.38 1.08 3.02E-16 1.10 9.54E-18 1.02 0.42 Gen 0.96 
rs13183209 44803749 G A 0.38 1.09 3.04E-16 1.11 7.72E-18 1.02 0.35 Imp 0.99 
rs6451774 44793984 G C 0.38 1.09 3.04E-16 1.10 8.79E-18 1.02 0.35 Imp 0.99 
rs10063172 44930709 T C 0.61 0.92 3.11E-16 0.90 7.55E-18 0.98 0.35 Imp 0.99 
rs6451778 44857988 C T 0.62 0.92 3.12E-16 0.90 8.11E-18 0.98 0.34 Imp 0.99 
rs10039866 44925061 T A 0.61 0.92 3.13E-16 0.90 5.21E-18 0.98 0.35 Gen 1.00 
rs11948636 44881229 A C 0.61 0.92 3.15E-16 0.91 1.00E-17 0.98 0.34 Gen 1.00 
rs34115673 44892801 T G 0.61 0.92 3.20E-16 0.91 8.96E-18 0.98 0.36 Imp 0.98 
rs10035358 44892902 C A 0.61 0.92 3.21E-16 0.91 8.71E-18 0.98 0.36 Imp 0.98 
rs10072025 44843494 C T 0.62 0.92 3.22E-16 0.90 5.21E-18 0.98 0.34 Imp 0.99 
rs6875933 44786696 C T 0.38 1.09 3.26E-16 1.11 6.99E-18 1.02 0.35 Imp 0.97 
rs11750119 44786141 G T 0.38 1.09 3.29E-16 1.11 6.37E-18 1.02 0.35 Imp 0.99 
rs13154729 44892929 C T 0.61 0.92 3.30E-16 0.91 9.07E-18 0.98 0.36 Imp 0.99 
rs10057341 44931840 C T 0.61 0.92 3.34E-16 0.90 6.56E-18 0.98 0.36 Gen 1.00 
chr5:44904186:D 44904186 CACTTA C 0.59 0.92 3.37E-16 0.90 1.97E-17 0.98 0.43 Imp 0.94 
rs13153556 44928101 G A 0.61 0.92 3.40E-16 0.90 6.16E-18 0.98 0.36 Gen 1.00 
rs10059086 44872007 C T 0.61 0.92 3.42E-16 0.91 1.13E-17 0.98 0.34 Gen 1.00 
rs2330619 44796062 T C 0.38 1.08 3.43E-16 1.10 9.62E-18 1.02 0.36 Imp 0.99 
rs13168400 44883536 C T 0.61 0.92 3.45E-16 0.91 1.22E-17 0.98 0.36 Imp 0.99 
rs67274820 44782295 T C 0.38 1.08 3.50E-16 1.11 7.18E-18 1.02 0.37 Imp 0.99 
chr5:44795637:I 44795637 G GA 0.38 1.08 3.51E-16 1.11 8.66E-18 1.02 0.36 Imp 0.99 
 rs10069220 44881978 G A 0.61 0.92 3.53E-16 0.91 1.05E-17 0.98 0.33 Gen 1.00 
rs4495192 44929177 T C 0.62 0.92 3.56E-16 0.90 5.47E-18 0.98 0.35 Imp 0.99 
rs13157608 44881504 C T 0.61 0.92 3.62E-16 0.91 1.27E-17 0.98 0.36 Imp 0.99 
rs10941687 44921183 G A 0.62 0.92 3.67E-16 0.90 6.65E-18 0.98 0.35 Imp 0.99 
rs10040488 44880288 G T 0.62 0.92 3.69E-16 0.91 1.30E-17 0.98 0.36 Imp 0.99 
rs9637783 44819646 T G 0.39 1.08 3.70E-16 1.11 6.26E-18 1.02 0.37 Gen 1.00 
rs4866920 44879146 G T 0.62 0.92 3.76E-16 0.91 1.35E-17 0.98 0.36 Imp 0.99 
rs10473376 44931228 C T 0.62 0.92 3.79E-16 0.90 7.90E-18 0.98 0.36 Imp 0.99 
rs4591754 44895091 G A 0.62 0.92 3.80E-16 0.91 9.81E-18 0.98 0.36 Imp 0.99 
rs7356604 44895199 T C 0.62 0.92 3.80E-16 0.91 9.82E-18 0.98 0.36 Imp 0.99 
rs12652026 44798609 C T 0.38 1.08 3.83E-16 1.11 8.81E-18 1.02 0.36 Imp 0.99 
rs4642377 44885240 A T 0.61 0.92 3.84E-16 0.91 1.40E-17 0.98 0.35 Imp 0.99 
rs6875287 44941630 C T 0.39 1.09 3.85E-16 1.10 1.44E-17 1.02 0.32 Imp 0.98 
rs10042455 44925018 A G 0.62 0.92 3.91E-16 0.90 6.70E-18 0.98 0.35 Imp 0.99 
rs13187933 44883243 T C 0.62 0.92 3.93E-16 0.91 1.08E-17 0.98 0.36 Imp 0.99 
rs6883465 44891620 T C 0.62 0.92 4.01E-16 0.91 9.16E-18 0.98 0.37 Imp 0.99 
rs4391175 44890056 A G 0.62 0.92 4.03E-16 0.90 9.00E-18 0.98 0.37 Imp 0.99 
rs10070037 44870237 A T 0.61 0.92 4.07E-16 0.91 1.06E-17 0.98 0.37 Gen 1.00 
rs7718354 44891014 T G 0.62 0.92 4.08E-16 0.91 9.29E-18 0.98 0.37 Imp 0.99 
rs7734331 44895588 G A 0.62 0.92 4.13E-16 0.91 9.36E-18 0.98 0.37 Imp 0.99 
rs11948387 44884241 T C 0.62 0.92 4.16E-16 0.91 1.13E-17 0.98 0.36 Imp 0.99 
rs6859157 44783838 G A 0.38 1.08 4.17E-16 1.11 8.33E-18 1.02 0.37 Imp 0.99 
rs11958451 44866902 A G 0.61 0.92 4.20E-16 0.91 1.53E-17 0.98 0.35 Imp 0.99 
rs4323241 44929156 T C 0.61 0.92 4.28E-16 0.90 1.72E-17 0.98 0.33 Imp 0.97 
rs10060878 44899424 T C 0.61 0.92 4.37E-16 0.91 8.78E-18 0.98 0.36 Gen 1.00 
rs6894324 44867336 G C 0.62 0.92 4.37E-16 0.91 1.38E-17 0.98 0.35 Imp 0.99 
rs10040082 44865854 T C 0.62 0.92 4.43E-16 0.91 1.50E-17 0.98 0.34 Gen 1.00 
rs9292914 44871381 A C 0.61 0.92 4.45E-16 0.91 1.23E-17 0.98 0.37 Gen 1.00 
rs10065638 44866162 T C 0.61 0.92 4.48E-16 0.91 1.39E-17 0.98 0.34 Gen 0.98 
rs10473377 44931246 T C 0.62 0.92 4.49E-16 0.90 8.71E-18 0.98 0.35 Imp 0.99 
rs34501299 44913079 T G 0.61 0.92 4.50E-16 0.91 1.16E-17 0.98 0.38 Gen 1.00 
rs4395640 44869100 T C 0.62 0.92 4.53E-16 0.91 1.47E-17 0.98 0.35 Gen 1.00 
rs7708686 44922838 C G 0.62 0.92 4.69E-16 0.90 7.26E-18 0.98 0.35 Imp 0.99 
rs7708506 44922704 C G 0.62 0.92 4.73E-16 0.90 7.31E-18 0.98 0.35 Imp 0.99 
rs12109710 44929928 A G 0.62 0.92 4.74E-16 0.90 9.42E-18 0.98 0.35 Imp 0.98 
rs6868779 44886000 A G 0.61 0.92 4.80E-16 0.91 1.42E-17 0.98 0.36 Gen 1.00 
rs13356086 44887679 T C 0.62 0.92 4.84E-16 0.91 1.08E-17 0.98 0.37 Imp 0.98 
rs11951760 44872172 G A 0.62 0.92 4.97E-16 0.91 1.18E-17 0.98 0.39 Imp 0.99 
rs4866784 44901131 T C 0.61 0.92 5.05E-16 0.91 1.01E-17 0.98 0.38 Gen 1.00 
rs10057521 44865986 C T 0.60 0.92 5.07E-16 0.91 1.51E-17 0.98 0.36 Gen 0.95 
rs4129642 44898129 G T 0.61 0.92 5.12E-16 0.91 9.43E-18 0.98 0.36 Gen 1.00 
 rs6881563 44912853 C T 0.61 0.92 5.28E-16 0.91 1.38E-17 0.98 0.38 Gen 1.00 
rs4866783 44876507 C T 0.62 0.92 5.62E-16 0.91 1.38E-17 0.98 0.39 Imp 0.98 
rs7708705 44922925 A G 0.62 0.92 5.67E-16 0.90 7.88E-18 0.98 0.35 Imp 0.98 
rs10039173 44903376 C T 0.61 0.92 5.74E-16 0.91 1.03E-17 0.98 0.41 Gen 1.00 
rs6870136 44910662 G A 0.61 0.92 5.76E-16 0.91 1.41E-17 0.98 0.40 Gen 1.00 
rs10060645 44908199 C T 0.61 0.92 6.23E-16 0.91 1.57E-17 0.98 0.40 Imp 0.99 
rs10045264 44886432 G A 0.61 0.92 6.24E-16 0.91 1.93E-17 0.98 0.36 Gen 1.00 
rs6880275 44908935 T C 0.62 0.92 7.75E-16 0.91 1.48E-17 0.98 0.41 Imp 0.99 
rs9791056 44903891 T C 0.61 0.92 8.09E-16 0.91 1.25E-17 0.98 0.41 Gen 1.00 
rs9791059 44900447 A C 0.62 0.92 8.13E-16 0.90 8.88E-18 0.98 0.42 Imp 0.98 
chr5:44904190:D 44904190 TAACTC T 0.61 0.92 8.31E-16 0.91 1.55E-17 0.98 0.41 Imp 0.99 
chr5:44842792:D 44842792 CT C 0.56 0.92 8.78E-16 0.90 3.54E-19 1.00 0.97 Imp 0.94 
chr5:44842794:D 44842794 CCAGTT C 0.56 0.92 8.80E-16 0.90 3.56E-19 1.00 0.97 Imp 0.94 
chr5:44842796:D 44842796 AGTTC A 0.56 0.92 8.80E-16 0.90 3.55E-19 1.00 0.97 Imp 0.94 
rs4457088 44900954 T A 0.62 0.92 8.85E-16 0.91 1.29E-17 0.98 0.41 Imp 0.99 
chr5:44782479:D 44782479 AT A 0.38 1.08 8.87E-16 1.10 1.30E-17 1.02 0.37 Imp 0.98 
rs4866921 44917137 T C 0.62 0.92 9.83E-16 0.91 1.34E-17 0.98 0.41 Imp 0.99 
rs9791164 44904030 A G 0.62 0.92 9.92E-16 0.91 1.70E-17 0.98 0.42 Imp 0.99 
rs6874167 44916674 G A 0.62 0.92 1.01E-15 0.91 1.49E-17 0.98 0.41 Imp 0.99 
rs4360054 44929004 A G 0.61 0.92 1.10E-15 0.91 2.52E-17 0.98 0.41 Imp 0.98 
rs6895062 44916492 T C 0.62 0.92 1.12E-15 0.91 1.84E-17 0.98 0.40 Imp 0.98 
chr5:44852861:D 44852861 AC A 0.61 0.92 1.59E-15 0.91 6.38E-17 0.98 0.31 Imp 0.96 
rs7449277 44841457 T A 0.60 0.92 2.06E-15 0.91 7.34E-17 0.98 0.35 Imp 0.95 
chr5:44885826:I 44885826 A AAATT 0.61 0.92 2.29E-15 0.90 1.66E-17 0.99 0.53 Imp 0.96 
rs7702464 44826259 A C 0.27 1.11 2.32E-15 1.13 6.87E-17 1.03 0.20 Imp 0.74 
chr5:44928978:D 44928978 ACCCTC 
CCCTTCT 
A 0.55 0.92 2.80E-15 0.90 3.15E-17 0.99 0.58 Imp 0.88 
chr5:44921956:I 44921956 T TA 0.61 0.92 3.19E-15 0.90 3.29E-17 0.99 0.54 Imp 0.95 
rs74724331 44758161 G A 0.40 1.08 3.28E-15 1.10 7.61E-17 1.01 0.47 Imp 0.95 
rs13178923 44929285 T A 0.57 0.92 1.03E-14 0.91 4.38E-15 0.98 0.34 Imp 0.87 
rs12658334 44689131 G A 0.39 1.09 2.72E-14 1.12 3.65E-16 1.02 0.50 Imp 0.73 
chr5:44832897:I 44832897 A ATGTT 0.59 0.93 5.26E-14 0.91 6.86E-16 0.99 0.79 Imp 0.94 
rs183946926 44688992 G A 0.37 1.09 1.05E-13 1.12 1.55E-16 1.03 0.25 Imp 0.69 
chr5:44868315:D 44868315 AAT A 0.48 0.93 1.26E-12 0.91 1.39E-13 0.97 0.13 Imp 0.79 
rs200229088 44701817 TTG T 0.31 1.09 2.28E-12 1.12 1.26E-13 1.04 0.15 Imp 0.65 
rs4562047 44868093 C T 0.48 0.93 1.52E-11 0.91 7.18E-14 0.99 0.68 Imp 0.77 
rs2067980 44982317 A G 0.16 1.09 2.51E-11 1.12 4.35E-13 1.04 0.17 Gen 1.00 
rs73093976 44609392 C T 0.17 1.09 6.67E-11 1.12 8.34E-13 1.02 0.36 Imp 0.95 
rs147039293 44673324 C T 0.14 0.92 3.98E-10 0.90 2.66E-10 0.93 0.01 Imp 0.96 
rs75209549 44629545 A G 0.14 1.09 6.64E-10 1.11 1.25E-10 1.02 0.53 Imp 0.89 
rs112234443 44922557 C T 0.05 1.16 1.10E-09 1.19 5.72E-10 1.07 0.14 Imp 0.90 
rs76001691 44633373 T C 0.05 1.16 1.14E-09 1.18 4.23E-09 1.09 0.07 Imp 0.82 
 rs4549535 44630291 A G 0.05 1.15 1.58E-09 1.17 9.53E-10 1.08 0.09 Imp 0.93 
rs6880469 44975989 A G 0.35 1.06 1.83E-09 1.08 2.19E-10 1.01 0.57 Imp 0.98 
rs6451787 45009269 T G 0.17 1.09 2.53E-09 1.11 2.10E-10 1.03 0.23 Imp 0.84 
rs28705196 44631795 T C 0.05 1.14 4.04E-09 1.17 1.01E-09 1.06 0.18 Imp 0.97 
chr5:44633359:I 44633359 T TTC 0.05 1.14 4.39E-09 1.17 1.36E-09 1.06 0.17 Imp 0.95 
chr5:44633372:I 44633372 T TC 0.05 1.14 4.39E-09 1.17 1.36E-09 1.06 0.17 Imp 0.95 
rs5004228 44632008 A G 0.05 1.14 4.63E-09 1.16 2.03E-09 1.07 0.13 Gen 1.00 
rs116443643 44606969 C A 0.15 0.92 5.30E-09 0.91 1.78E-09 0.95 0.04 Imp 0.95 
rs13357090 44632713 C T 0.05 1.14 7.05E-09 1.16 3.72E-09 1.07 0.12 Imp 0.96 
chr5:44681918:I 44681918 C CA 0.04 0.84 7.16E-09 0.82 3.71E-08 0.88 0.03 Imp 0.58 
c5_pos44839303 44803546 A G 0.14 0.92 7.49E-09 0.91 2.36E-08 0.93 0.01 Gen 1.00 
rs112754768 44718764 A G 0.05 1.15 8.65E-09 1.18 6.28E-09 1.06 0.19 Imp 0.88 
rs34692501 45029217 A G 0.13 1.09 9.49E-09 1.11 7.72E-10 1.03 0.30 Gen 1.00 
rs10941712 45917605 C T 0.23 0.93 9.61E-09 0.91 1.42E-10 0.95 0.02 Imp 0.78 
rs11750654 44494303 T C 0.15 0.92 1.13E-08 0.91 2.84E-09 0.95 0.04 Imp 0.95 
rs11750655 44494312 T C 0.15 0.92 1.13E-08 0.91 2.84E-09 0.95 0.04 Imp 0.95 
rs3935086 44960923 T A 0.33 1.06 1.14E-08 1.07 2.76E-09 1.01 0.64 Gen 1.00 
rs79670114 44861045 A G 0.04 1.16 1.24E-08 1.19 2.52E-09 1.06 0.23 Imp 0.88 
rs11742346 45003293 C T 0.13 1.09 1.29E-08 1.11 1.45E-09 1.03 0.24 Imp 0.94 
rs12520604 44476872 A C 0.04 1.16 1.34E-08 1.20 4.72E-09 1.03 0.56 Imp 0.91 
c5_pos44832736 44796979 C T 0.14 0.92 1.36E-08 0.91 4.34E-08 0.93 0.01 Gen 0.99 
c5_pos44671855 44636098 G C 0.20 0.93 1.41E-08 0.92 6.26E-09 0.96 0.10 Gen 1.00 
rs187108781 44619502 A G 0.15 0.92 1.59E-08 0.91 6.61E-09 0.95 0.04 Imp 0.95 
chr5:44795636:I 44795636 A AG 0.28 1.07 1.68E-08 1.09 9.96E-10 1.00 0.87 Imp 0.85 
c5_pos45369617 45333860 T C 0.26 0.94 1.71E-08 0.92 1.56E-10 0.96 0.05 Gen 1.00 
rs12516986 44526154 A G 0.04 1.15 1.80E-08 1.18 6.09E-09 1.03 0.50 Gen 1.00 
rs7702731 44914285 A G 0.68 0.94 2.80E-08 0.94 2.63E-08 0.99 0.71 Gen 0.98 
rs75036127 44802928 A T 0.04 1.15 3.47E-08 1.19 5.58E-09 1.05 0.33 Imp 0.88 
rs72748037 44449376 G A 0.15 0.93 3.51E-08 0.91 1.02E-08 0.95 0.04 Imp 0.97 
rs13183434 45074633 G A 0.13 1.08 3.67E-08 1.11 1.91E-09 1.04 0.21 Gen 1.00 
chr5:45943429:D 45943429 CTCT C 0.16 0.92 3.72E-08 0.89 1.09E-09 0.92 0.01 Imp 0.70 
rs11745472 44929256 A T 0.12 1.11 3.83E-08 1.13 5.18E-08 1.03 0.39 Imp 0.61 
rs72748026 44431924 C G 0.14 0.92 3.86E-08 0.91 3.78E-09 0.95 0.05 Imp 0.95 
rs17343002 44853593 G C 0.31 0.94 4.36E-08 0.94 9.13E-08 0.96 0.06 Gen 1.00 
c5_pos44489027 44453270 T G 0.15 0.93 4.89E-08 0.91 1.65E-08 0.95 0.04 Gen 1.00 
rs11738503 45011742 A G 0.16 1.08 5.09E-08 1.10 4.71E-09 1.04 0.19 Imp 0.87 
rs11741260 44412065 G A 0.14 0.93 5.14E-08 0.91 5.32E-09 0.95 0.05 Gen 1.00 
rs11948186 45051434 A G 0.34 1.06 5.17E-08 1.07 7.10E-09 1.01 0.69 Imp 0.97 
rs7701656 44947702 T C 0.13 1.08 5.71E-08 1.11 2.64E-09 1.00 0.90 Gen 1.00 
chr5:44692568:I 44692568 G GT 0.21 0.93 6.86E-08 0.92 8.13E-08 0.96 0.09 Imp 0.90 
rs78797445 44795797 G A 0.19 0.94 8.81E-08 0.93 1.30E-07 0.96 0.08 Imp 0.97 
 chr5:45162687:D 45162687 AGATCT A 0.14 0.93 1.03E-07 0.91 2.86E-08 0.93 0.01 Imp 0.95 
c5_pos44754116 44718359 G A 0.19 0.94 1.03E-07 0.93 1.25E-07 0.95 0.05 Gen 1.00 
rs111385188 44675187 G A 0.04 1.16 1.22E-07 1.19 2.96E-08 1.07 0.22 Imp 0.85 
rs62372990 45988038 G A 0.06 1.14 1.26E-07 1.15 3.53E-07 1.07 0.12 Imp 0.76 
c5_pos44754266 44718509 G A 0.07 1.11 1.27E-07 1.15 5.01E-10 1.04 0.30 Gen 1.00 
rs7293402 45990381 G A 0.06 1.13 1.40E-07 1.15 4.28E-07 1.07 0.13 Imp 0.76 
rs147872430 45239336 C T 0.14 0.93 1.52E-07 0.91 3.35E-08 0.93 0.01 Imp 0.96 
chr5:44945030:I 44945030 T TA 0.19 0.93 1.76E-07 0.93 3.34E-07 0.96 0.08 Imp 0.92 
rs10051592 45090306 T G 0.33 1.06 1.83E-07 1.07 1.67E-08 1.01 0.79 Gen 1.00 
c5_pos45171325 45135568 G C 0.14 0.93 1.97E-07 0.91 4.97E-08 0.93 0.01 Gen 1.00 
chr5:44518580:I 44518580 C CT 0.21 0.94 2.25E-07 0.93 2.21E-06 0.93 0.00 Imp 0.87 
rs11743309 45122388 A G 0.14 0.93 2.27E-07 0.92 8.71E-08 0.93 0.00 Gen 1.00 
c5_pos45322045 45286288 T A 0.14 0.93 2.61E-07 0.92 6.68E-08 0.94 0.01 Gen 0.99 
c5_pos45028737 44992980 G T 0.14 0.93 3.09E-07 0.92 1.57E-06 0.94 0.02 Gen 1.00 
c5_pos45149948 45114191 C T 0.14 0.93 3.74E-07 0.92 1.15E-07 0.93 0.01 Gen 1.00 
rs9763350 45882593 T C 0.26 1.07 4.25E-07 1.08 6.84E-07 1.08 0.00 Imp 0.71 
rs11740651 45302476 C A 0.14 0.93 7.20E-07 0.91 7.54E-08 0.94 0.03 Imp 0.91 
chr5:44976998:I 44976998 G GTGAT 0.11 1.08 9.83E-07 1.11 5.80E-08 1.02 0.44 Imp 0.93 
rs13172124 45160377 C T 0.46 0.95 1.13E-06 0.94 4.25E-07 0.98 0.22 Imp 0.96 
rs13186320 44302177 A T 0.47 1.05 1.19E-06 1.07 1.46E-07 1.04 0.05 Imp 0.86 
rs72750030 45903837 G A 0.11 0.92 1.26E-06 0.89 1.33E-07 0.92 0.02 Imp 0.70 
rs72751936 45984433 G A 0.11 0.91 1.33E-06 0.88 2.66E-07 0.90 0.01 Imp 0.59 
c5_pos45135048 45099291 G A 0.09 0.92 1.53E-06 0.91 7.00E-06 0.92 0.01 Gen 1.00 
rs147517548 44711323 C T 0.01 1.3 1.55E-06 1.37 5.35E-07 1.18 0.11 Imp 0.68 
rs13156720 44823321 A G 0.02 1.19 1.79E-06 1.25 1.18E-07 1.08 0.28 Imp 0.77 
c5_pos44444935 44409178 C A 0.06 0.91 1.90E-06 0.89 8.08E-07 0.95 0.18 Gen 1.00 
rs4866929 45266589 A G 0.47 0.95 1.98E-06 0.94 5.79E-07 0.98 0.21 Gen 1.00 
chr5:45210850:D 45210850 CTATAA 
AT 
C 0.45 0.95 2.02E-06 0.94 7.09E-07 0.97 0.17 Imp 0.92 
rs11959880 45958226 G A 0.09 0.9 2.06E-06 0.89 2.01E-06 0.90 0.01 Imp 0.58 
rs17268417 44700201 T C 0.05 1.12 2.08E-06 1.15 4.60E-07 1.08 0.07 Gen 0.95 
chr5:45210851:D 45210851 TATAAA 
TTACC 
T 0.45 0.95 2.31E-06 0.94 7.39E-07 0.97 0.16 Imp 0.92 
chr5:44349569:D 44349569 AT AGA T 0.43 1.06 2.33E-06 1.06 3.88E-06 1.03 0.22 Imp 0.70 
rs11738948 44999799 G C 0.20 0.94 2.45E-06 0.94 1.32E-05 0.95 0.05 Imp 0.96 
rs72750027 45899603 G A 0.01 1.43 2.55E-06 1.46 1.45E-05 1.42 0.01 Imp 0.66 
rs72765759 45846620 C T 0.11 0.92 2.91E-06 0.90 2.28E-07 0.94 0.06 Imp 0.73 
rs981782 45285718 A C 0.47 0.96 3.13E-06 0.95 8.27E-07 0.98 0.30 Imp 0.97 
rs137877813 45084544 G C 0.14 0.94 3.13E-06 0.93 4.96E-06 0.94 0.02 Imp 0.96 
rs138117035 45938300 T C 0.10 0.91 3.23E-06 0.89 7.08E-07 0.93 0.05 Imp 0.61 
rs145696903 45933347 G A 0.10 0.91 3.38E-06 0.89 9.01E-07 0.92 0.04 Imp 0.61 
chr5:44302175:D 44302175 CA C 0.51 1.05 3.46E-06 1.06 3.54E-07 1.03 0.17 Imp 0.94 
rs75442098 44498735 C A 0.03 0.86 3.56E-06 0.84 1.40E-05 0.91 0.15 Imp 0.65 
 rs16902086 45285752 A G 0.34 1.05 3.60E-06 1.06 6.45E-07 1.02 0.34 Gen 1.00 
rs72762052 45427937 C T 0.13 0.93 3.83E-06 0.91 6.81E-07 0.93 0.03 Imp 0.81 
rs72750038 45912279 T C 0.10 0.91 3.87E-06 0.89 1.15E-06 0.92 0.02 Imp 0.65 
rs74833952 44961224 G A 0.02 0.76 4.76E-06 0.75 2.64E-05 0.80 0.06 Imp 0.42 
rs11747840 44984579 C T 0.21 0.95 4.97E-06 0.94 1.74E-05 0.96 0.08 Imp 0.94 
rs72751917 45949866 G A 0.01 1.4 5.21E-06 1.40 6.02E-05 1.38 0.02 Imp 0.51 
rs11750845 44373060 C T 0.51 1.05 5.39E-06 1.06 4.54E-07 1.02 0.27 Gen 1.00 
rs72759922 45005236 C T 0.21 0.95 6.67E-06 0.94 1.09E-05 0.97 0.16 Imp 0.94 
rs72763959 45707287 C A 0.01 1.33 6.84E-06 1.36 3.85E-05 1.28 0.03 Imp 0.69 
rs35190075 44776604 C G 0.02 1.18 7.49E-06 1.25 5.20E-07 1.11 0.15 Imp 0.76 
rs185330077 45366544 G A 0.01 1.48 7.60E-06 1.69 9.92E-08 0.94 0.70 Imp 0.39 
rs182455548 45746470 G A 0.01 1.33 7.67E-06 1.35 3.70E-05 1.28 0.04 Imp 0.69 
rs72763975 45767075 G A 0.01 1.33 7.78E-06 1.35 3.66E-05 1.28 0.04 Imp 0.69 
c5_pos44897529 44861772 T C 0.04 1.11 8.41E-06 1.14 9.56E-07 1.05 0.26 Gen 1.00 
rs72763992 45806419 A T 0.01 1.33 8.60E-06 1.36 3.32E-05 1.28 0.04 Imp 0.67 
rs148456234 45922475 C T 0.11 0.92 8.93E-06 0.90 1.29E-06 0.93 0.05 Imp 0.65 
rs72750006 45862423 A G 0.01 1.3 8.95E-06 1.35 1.57E-05 1.24 0.05 Imp 0.63 
rs72762048 45408899 T C 0.12 0.93 9.74E-06 0.91 2.49E-06 0.93 0.03 Imp 0.80 
rs5003385 44907327 A C 0.04 1.11 1.01E-05 1.14 9.29E-07 1.05 0.27 Gen 1.00 
rs191491730 45160378 G A 0.00 1.6 1.03E-05 1.83 4.17E-07 1.21 0.37 Imp 0.59 
rs148415520 45317307 G A 0.45 0.96 1.13E-05 0.95 6.59E-06 0.97 0.12 Imp 0.91 
rs76810418 45882608 G A 0.25 1.06 1.21E-05 1.07 1.71E-05 1.06 0.02 Imp 0.74 
chr5:44606887:D 44606887 AT A 0.15 0.94 1.28E-05 0.93 2.00E-05 0.97 0.26 Imp 0.95 
rs147763247 45313905 G C 0.45 0.96 1.32E-05 0.95 6.73E-06 0.97 0.12 Imp 0.91 
rs10473395 45882607 T C 0.25 1.06 1.52E-05 1.07 2.30E-05 1.06 0.02 Imp 0.74 
chr5:45799799:D 45799799 AT A 0.04 1.12 1.59E-05 1.13 5.54E-05 1.06 0.26 Imp 0.81 
rs192741232 44838737 A G 0.01 1.3 1.59E-05 1.38 4.74E-06 1.14 0.27 Imp 0.75 
rs150276216 44889423 T C 0.04 1.11 1.71E-05 1.14 2.26E-06 1.06 0.26 Imp 0.97 
rs191712805 45795107 A G 0.01 1.33 1.72E-05 1.36 5.89E-05 1.28 0.05 Imp 0.61 
rs4613718 44649944 C T 0.60 1.04 1.92E-05 1.06 5.73E-07 0.98 0.22 Gen 1.00 
rs114416420 45951524 G T 0.10 0.91 2.00E-05 0.90 3.06E-05 0.90 0.01 Imp 0.56 
c5_pos44663080 44627323 C T 0.21 0.95 2.02E-05 0.95 4.76E-05 0.95 0.04 Gen 1.00 
rs180724159 45562846 T C 0.00 1.53 2.04E-05 1.71 1.34E-06 1.20 0.36 Imp 0.72 
rs181673846 45837084 C A 0.01 1.34 2.08E-05 1.38 4.81E-05 1.29 0.05 Imp 0.69 
chr5:45853664:D 45853664 CAT C 0.02 1.22 2.15E-05 1.22 1.25E-04 1.10 0.30 Imp 0.58 
rs139424826 45522979 C A 0.12 0.93 2.44E-05 0.90 1.23E-06 0.94 0.10 Imp 0.68 
rs6859397 45136050 T C 0.33 1.04 2.79E-05 1.06 4.14E-06 1.00 0.83 Imp 0.95 
rs4492120 45187804 G A 0.33 1.04 2.82E-05 1.06 2.90E-06 1.00 0.81 Gen 1.00 
chr5:44349567:D 44349567 TATAT 
CAGA 
T 0.38 1.05 2.86E-05 1.06 2.14E-05 1.02 0.43 Imp 0.69 
rs10035564 45252500 A G 0.34 1.04 2.98E-05 1.06 2.91E-06 1.01 0.72 Gen 0.96 
rs75513092 44544909 G T 0.21 0.95 3.22E-05 0.95 6.48E-05 0.96 0.06 Imp 0.98 
 rs6867827 45317216 G T 0.17 1.06 3.36E-05 1.06 5.26E-05 1.04 0.11 Imp 0.97 
rs139928702 45938421 A C 0.05 1.12 3.47E-05 1.13 1.02E-04 1.08 0.18 Imp 0.62 
rs11748830 44265513 C T 0.16 0.94 3.70E-05 0.94 3.87E-05 0.94 0.02 Imp 0.92 
rs17268006 44538881 C T 0.21 0.95 4.19E-05 0.95 9.20E-05 0.96 0.05 Gen 0.99 
chr5:45686224:D 45686224 TA T 0.07 1.12 4.22E-05 1.09 5.64E-03 1.15 0.01 Imp 0.50 
chr5:44816722:D 44816722 ACTT A 0.04 1.11 4.29E-05 1.14 7.24E-06 1.07 0.18 Imp 0.95 
rs72759920 44998794 T G 0.04 1.11 5.13E-05 1.13 1.88E-05 1.06 0.21 Imp 0.92 
rs72759916 44990010 T C 0.04 1.11 6.09E-05 1.13 1.69E-05 1.06 0.24 Imp 0.92 
rs62370579 45792329 A T 0.03 1.15 6.40E-05 1.15 7.86E-04 1.10 0.17 Imp 0.77 
chr5:45843775:D 45843775 TTA T 0.04 1.12 6.78E-05 1.13 2.15E-04 1.06 0.29 Imp 0.84 
rs181701912 44888831 C T 0.11 0.92 6.92E-05 0.90 2.49E-05 0.96 0.36 Imp 0.51 
rs10078961 44888856 T C 0.29 0.95 7.00E-05 0.93 8.16E-06 0.99 0.73 Imp 0.63 
chr5:45379590:D 45379590 CA C 0.19 1.05 7.02E-05 1.06 7.32E-05 1.04 0.15 Imp 0.97 
rs75946047 44454153 C T 0.03 1.14 7.34E-05 1.20 6.92E-06 1.08 0.26 Imp 0.81 
rs62372989 45987296 A G 0.03 1.14 7.45E-05 1.15 3.22E-04 1.07 0.31 Imp 0.70 
rs12187122 44577879 A G 0.03 1.13 7.77E-05 1.16 3.14E-05 1.01 0.93 Imp 0.91 
rs6451798 45387854 C T 0.19 1.05 7.93E-05 1.06 8.43E-05 1.03 0.16 Gen 1.00 
rs62370581 45793718 G A 0.03 1.12 8.32E-05 1.12 3.67E-04 1.06 0.28 Imp 0.91 
rs1816683 44701827 G A 0.57 1.04 8.34E-05 1.06 2.73E-06 0.98 0.30 Imp 0.85 
rs75964308 45946479 G C 0.04 1.12 8.48E-05 1.13 2.36E-04 1.06 0.33 Imp 0.77 
rs1501362 45378207 C T 0.19 1.05 8.52E-05 1.06 7.26E-05 1.03 0.18 Imp 0.98 
rs141075872 45790426 A T 0.03 1.13 8.55E-05 1.13 7.34E-04 1.07 0.25 Imp 0.82 
rs7709262 45342044 A G 0.19 1.05 8.69E-05 1.06 8.62E-05 1.03 0.18 Imp 0.98 
rs144163740 45376455 G T 0.36 0.95 8.87E-05 0.94 3.12E-05 0.98 0.52 Imp 0.61 
rs62370604 45843007 T C 0.03 1.12 9.55E-05 1.13 3.17E-04 1.06 0.32 Imp 0.86 
rs74859464 45951751 C A 0.03 1.12 9.58E-05 1.13 2.33E-04 1.06 0.33 Imp 0.83 
rs6874127 45305615 A G 0.19 1.05 9.63E-05 1.06 9.12E-05 1.03 0.17 Gen 1.00 
rs75212852 45805592 C T 0.03 1.12 9.76E-05 1.12 4.25E-04 1.06 0.29 Imp 0.91 
chr5:45804917:I 45804917 T TA 0.03 1.12 9.79E-05 1.12 4.27E-04 1.06 0.29 Imp 0.91 
c5_pos45103929 45068172 G A 0.04 1.1 9.85E-05 1.12 1.27E-04 1.05 0.31 Gen 1.00 
 
 
 Supplementary Table 2. The three independent signals showing the lead SNP in each signal together with the correlated 
SNPs that could not be excluded from causality.  
 
SNP  Position Ref/Alt MAF 
Imput-
ation 
r2 
OR (95% CI) 
Single 
SNP 
p_value 
P-value 
condition
al on 
signal 1 
top hit 
P-value 
conditio
nal on 
signal 1 
+ 2 
cor_ 
rs109416
79 
cor_rs68
64776 
cor_ 
rs200229
088 
Signal 1 
rs10941679 44706498 A/G 0.27 0.99 1.12(1.1-1.15) 2.60E-26 NA NA 1.00 0.07 0.14 
Signal 2 
rs6864776 44513304 G/A 0.23 0.97 1.04(1.02-1.06) 0.00078 6.22E-11 NA 0.07 1.00 0.05 
chr5.44527739.I 44527739 ATACT/A 0.24 0.96 1.04(1.02-1.07) 0.00044 6.40E-11 NA 0.06 0.98 0.05 
rs4634356 44553611 C/T 0.23 0.99 1.04(1.02-1.06) 0.00076 7.89E-11 NA 0.07 0.99 0.06 
rs1905192 44531538 A/T 0.23 0.99 1.04(1.02-1.06) 0.00077 8.76E-11 NA 0.07 0.99 0.06 
rs4866905 44555867 C/T 0.23 1.00 1.04(1.02-1.06) 0.00086 1.02E-10 NA 0.07 0.98 0.06 
rs1482663 44543102 A/G 0.23 1.00 1.04(1.02-1.06) 0.00085 1.04E-10 NA 0.07 0.99 0.06 
chr5.44496660.I 44496660 AG/A 0.23 0.98 1.04(1.02-1.06) 0.00087 1.04E-10 NA 0.06 0.99 0.05 
rs7710996 44514350 G/A 0.23 0.99 1.04(1.02-1.06) 0.00085 1.07E-10 NA 0.06 0.99 0.05 
rs6451763 44527841 C/A 0.23 0.99 1.04(1.02-1.06) 0.00087 1.09E-10 NA 0.07 0.99 0.05 
c5_pos44562807 44527050 A/C 0.23 1.00 1.04(1.02-1.06) 0.00087 1.15E-10 NA 0.07 0.99 0.06 
rs1351633 44543851 C/T 0.23 0.99 1.04(1.02-1.06) 0.00094 1.18E-10 NA 0.07 0.99 0.06 
rs1384453 44496114 T/C 0.23 0.99 1.04(1.02-1.06) 0.00091 1.20E-10 NA 0.06 0.99 0.05 
rs1482665 44546628 G/A 0.23 1.00 1.04(1.02-1.06) 0.00093 1.20E-10 NA 0.07 0.99 0.06 
rs983940 44544136 G/A 0.23 0.99 1.04(1.02-1.06) 0.00095 1.21E-10 NA 0.07 0.99 0.06 
rs6897963 44554781 C/A 0.23 1.00 1.04(1.02-1.06) 0.00098 1.33E-10 NA 0.07 0.98 0.06 
rs1384454 44492998 C/T 0.23 0.99 1.04(1.02-1.06) 0.00098 1.43E-10 NA 0.06 0.99 0.05 
rs10079222 44561473 G/C 0.23 1.00 1.04(1.02-1.06) 0.001 1.45E-10 NA 0.07 0.98 0.06 
rs7736427 44524276 A/G 0.25 0.93 1.04(1.02-1.07) 0.00028 1.48E-10 NA 0.05 0.94 0.05 
rs10512860 44539953 G/C 0.23 1.00 1.04(1.02-1.06) 0.001 1.50E-10 NA 0.07 0.99 0.05 
rs4866776 44525589 T/A 0.23 1.00 1.04(1.02-1.06) 0.001 1.52E-10 NA 0.07 0.99 0.05 
rs1482690 44488840 T/A 0.24 0.98 1.04(1.02-1.06) 0.0011 1.91E-10 NA 0.06 0.99 0.05 
rs12516346 44488156 A/C 0.23 0.99 1.04(1.01-1.06) 0.0016 2.39E-10 NA 0.07 0.97 0.06 
rs1482684 44478742 G/A 0.23 1.00 1.04(1.01-1.06) 0.0013 2.41E-10 NA 0.06 0.99 0.05 
chr5.44496659.I 44496659 TA/T 0.25 0.93 1.04(1.01-1.06) 0.0017 2.41E-10 NA 0.07 0.95 0.05 
rs1482691 44487477 C/A 0.23 0.99 1.04(1.01-1.06) 0.0013 2.52E-10 NA 0.06 0.99 0.05 
rs7724859 44471395 T/C 0.23 1.00 1.04(1.01-1.06) 0.0014 2.84E-10 NA 0.06 0.99 0.05 
rs2128430 44462926 T/C 0.23 0.99 1.04(1.01-1.06) 0.0014 3.03E-10 NA 0.06 0.99 0.05 
rs7707044 44471392 A/T 0.23 1.00 1.04(1.01-1.06) 0.0015 3.15E-10 NA 0.06 0.99 0.05 
rs1905191 44456782 C/T 0.23 0.98 1.04(1.01-1.06) 0.0015 3.21E-10 NA 0.06 0.99 0.05 
 rs1120718 44466578 T/C 0.23 1.00 1.04(1.01-1.06) 0.0017 3.86E-10 NA 0.06 0.99 0.05 
rs4866899 44444857 C/T 0.23 0.98 1.04(1.01-1.06) 0.0017 4.49E-10 NA 0.06 0.98 0.05 
rs7712213 44451269 A/C 0.23 0.98 1.04(1.01-1.06) 0.002 5.30E-10 NA 0.07 0.98 0.05 
rs6451762 44463186 C/T 0.24 0.96 1.04(1.01-1.06) 0.0023 7.36E-10 NA 0.06 0.98 0.05 
rs7703171 44441175 C/T 0.23 0.95 1.04(1.01-1.06) 0.0018 8.24E-10 NA 0.06 0.95 0.05 
rs6879342 44473605 A/G 0.24 0.98 1.03(1.01-1.06) 0.0067 3.57E-09 NA 0.07 0.96 0.06 
Signal 3 
rs200229088 44701817 TTG/T 0.31 0.65 1.09(1.07-1.12) 2.30E-12 5.61E-04 1.12E-05 0.14 0.05 1.00 
 
 
  
 Supplementary Table 3. ER/PR status, genotype and copy number at 5p12 of breast cell lines used in functional assays. 
 
 
 
 
 
aEstrogen receptor-alpha, bProgesterone receptor, cCopy number status from array CGH data (segmentation of 
normalized log2 ratios) generated by the Cancer Cell Line Encyclopedia (CCLE), Not det = Not determined. 
  
ERa PRb Signal 1 Signal 2 Signal 3 Copy
status status rs10941679 rs6864776 rs200229088 Numberc Haplotype
SVCT − − AA GG TTG/T Not det A/B
MCF10A − − AA GG TTG/T Not det A/B
T47D + + AA AA TTG/T Gain C/D
ZR751 + + AA AA TTG/T Normal C/D
MDA-MB-361 + − AA AA TTG/T Gain C/D
MCF7 + + AA AG TTG/T Gain Not det
Hs578T − − AA AG TTG/T Gain Not det
BT474 + + AG AG TTG/T Gain Not det
Bre80 − − AG AG TTG/T Not det Not det
MDA-MB-231 − − AG AG TTG/T Gain Not det
BT-20 − − GG AA TTG/T Gain G/H
MDA-MB-468 − − GG AA TTG/T Gain G/H
 Supplementary Table 4. Oligonucleotides used for qRTPCR of putative noncoding RNAs. 
 
qRT Primer Sequence (5’ to 3’) 
FGF10-AS1FOR TGCACCAACATCCATAACTCCTCG 
FGF10-AS1REV CTTTGTGAAGGAAAGCTGGACAGG 
BRCAT54FOR TGTGTGCTTAGACCTGACGCTGG 
BRCAT54REV CTCCTCACATGGCAGGAAGAAGG 
RP11-503D12.1FOR CAAGGTCAGTTGGCATTGTTCTGG 
RP11-503D12.1REV CAACCACCATGTCAAGGAACTCTAGC 
RP11-473L15.3FOR CACATGCATTGGCTATGACCTTGC 
RP11-473L15.3REV GCTGGCCATAAAGCTTCAATGTCC 
TATA-binding proteinFOR CATGGATCAGAACAACAGCCTGC 
TATA-binding proteinREV TTGTGAGAGTCTGTGAGTGGAAGAGC 
 
 
Supplementary Table 5. Cell lines used in the study. 
 
Cell line1,2 Source 
SVCT ECACC 94122105 
MCF10A ATCC CRL-10317 
T47D ATCC HTB-133 
ZR751 ATCC CRL-1500 
MDA-MB-361 Gift from S. Lankani, UQCCR, AUS 
MCF7 ATCC HTB-22 
Hs578T ATCC HTB-126 
BT474 ATCC HTB-20 
Bre80 Gift from R. Reddel, CMRI, AUS 
MDA-MB-231 ATCC HTB-26 
BT-20 ATCC HTB-19 
MDA-MB-468 ATCC HTB-132 
 
1 Cell lines used in experiments were within passages 15-30. 
2 Cell lines were routinely tested for mycoplasma and short tandem repeat (STR) profiled.  
 Supplementary Table 6. Oligonucleotides used in 3C assays. 
 
3C Primer (EcoRI) Sequence (5’ to 3’) 
FGF10 promoter bait GCTGCTCTTCTGTACAGCGTGATGACAAGAGG 
MRPS30 promoter bait CCTTCACAGAAGTAAGCAACATGAGGGAAGC 
HCN1 promoter bait TCCCACTGGCACCTGCAAGTATGTGC 
PRE Fragment 1 CTAAGACTGTCTCACCATGGAGCAACTCATGC 
PRE Fragment 2 TGGCTTCCTGCCACTTGTTTCCTAATGC 
PRE Fragment 3 CTCCTTGCTGTGAGAAGGTTGCACATCC 
PRE Fragment 4 AGCACAAGAGCAGCCTCTACTGGGATATGC 
PRE Fragment 5 TCCAAGTGAGTCAGTCTCCTGCCTCAGG 
PRE Fragment 6 TCACTTGCTTTCTAGATTTGTGATTCTGCTTTCC 
PRE Fragment 7 GTCCAGAGTCAAGTGGAGGAGATAACTCAAGGG 
PRE Fragment 8 GAGGAATCAGGCAATCTTCATAAATATGGCTTACC 
PRE Fragment 9 GGAATGCAAAGTGCAGCTATTGCTCTGC  
PRE Fragment 10 GAAAATTTGGCATCATCCTTAGTGCACAGTAGG  
PRE Fragment 11 CTGTGTAAGTTACAGAGCCATGATCATTGGTGG 
PRE Fragment 12 GCCACATCCCTAGATGCCATGGTCC  
  
 Supplementary Table 7. Oligonucleotides used in cloning luciferase constructs. 
 
Primer Sequence (5’ to 3’) 
FGF10 promoter FOR GATCGCCATAAAGTGCGTTTGC 
FGF10 promoter REV CTGGAAGGGTAAGACCCGATGC 
FGF10-AS1 promoter FOR CCCAGGCATAATTTACGCTGAGG 
FGF10-AS1 promoter REV GCATTCACTTCTGGCCAGATCC 
MRPS30 promoter FOR ACTTTCCATGGCTCTGACTCAGTCC 
MRPS30 promoter REV CGGACCCAGAGGTCAACTTAAGC 
BRCAT54 promoter FOR CCTATCGTGAACGGTTATTGTGAGC 
BRCAT54 promoter REV AGTTCCTGGCAAAGGAGGTTGC 
5p12 enhancer FOR GACTCTGTATCTTCACGCATTTCCAGG 
5p12 enhancer REV TTAGAGACCAGAAATGTGGGCAAAGG 
rs10941679 mut FOR GCTTTTTATTGACTGTGGAAAGAACACAGC 
rs10941679 mut REV GCTGTGTTCTTTCCACAGTCAATAAAAAGC 
 
 
 
 
Supplementary Table 8. Oligonucleotides used in EMSAs. 
 
SNP allelea Sequence (5’ to 3’)b 
rs10941679 com BIOGCTTTTTATTGACTATGGAAAGAACACAGC 
rs10941679 min BIOGCTTTTTATTGACTGTGGAAAGAACACAGC 
Neg control   AGAGATTGCCTGACGTCAGAGAGCTAG 
 
a com: common allele, min: minor allele 
b BIO: 5’ biotinylation (present on both the sense and antisense strands of the duplex) 
 
 
 
 
  
 Supplementary Table 9. EMSA competitor duplexes and their target DNA binding proteins. 
 
Competition Target 
Sequence (5’ to 3’) 
AP1 CGCTTGATGACTCAGCCGGAA 
AP2 GATCGAACTGACCGCCCGCGGCCCGT 
CEBP TGCAGATTGCGCAATCTGCA 
CTCF AAGAAACCGCTAGGGGGCCTACT 
FOXA1 CTGGTCTTAAAGGTGTTTACCTTGTCTGAT 
FOXA2 GTTGACTAAGTCAATAATCAGAATCAG 
GATA3 CACTTGATAACAGAAAGTGATAACTCT 
HNF6 GATTCCATATTGATTTCAAAA 
HOXA10 GCATTCAGAAGGTTATAGCTTT 
MYC TCAGACCACGTGGTCGGG 
NFkB AGTTGAGGGGACTTTCCCAGGC 
OCT1 TGTCGAATGCAAATCACTAGAA 
SP1 ATTCGATCGGGGCGGGGCGAGC 
 
 
 
Supplementary Table 10. Oligonucleotides used for ChIP-qPCR analyses. 
 
Name Sequence (5’ to 3’) 
ChIP rs10941679 FOR TTGAATCAGATGTGTAGTGCTTCC 
ChIP rs10941679 REV AACCTGAATGCAGCAAAATAGC 
ChIP negcontrol FOR CTAAGGACGAGATGCACATGG 
ChIP negcontrol REV TCAAGTTTCCAACTCCAACAGG 
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